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DISSERTATION ABSTRACT 
 
Maire F. Osborn 
 
Doctor of Philosophy 
 
Department of Chemistry and Biochemistry 
 
March 2014 
 
Title: Cellular RNA Targeting by Platinum (II) Anticancer Therapeutics 
 
 
Cis-diamminedichloroplatinum (II), or cisplatin, is a widely prescribed anticancer 
compound, currently one of only three platinum (II) complexes FDA approved for cancer 
treatment. Despite its widespread use, we lack a comprehensive picture of global drug 
targets, which would lend valuable insights into the molecular mechanisms of action and 
resistance in different tissues. Drug binding to genomic DNA is an accepted cause of 
downstream apoptotic signaling, but less than 10% of Pt (in the case of cisplatin) 
accumulates within genomic DNA. Non-genomic contributions to cisplatin’s therapeutic 
action are also under active investigation. In particular, cisplatin treatment can disrupt 
RNA-based processes such as splicing and translation. Pt(II) targeting of non-DNA 
species such as RNA may contribute to or sensitize a cell to the downstream effects of 
this drug, including the induction of apoptosis.  
Chapter I summarizes the activity profile of Pt(II) therapeutics, describing cellular 
uptake, cellular localization, incidences of Pt(II) accumulation within RNA, and RNA 
processes affected following drug treatment. Chapter II reports our thorough 
investigation of the distribution of Pt species throughout messenger and ribosomal RNA, 
with the discovery that Saccharomyces cerevisiae ribosomes act as a de facto cellular Pt 
sponge. In Chapter III, we report the synthesis of an azide-functionalized platinum (II) 
	   v 
species, picazoplatin, for post-treatment click labeling and isolation of drug targets in 
vivo. Picazoplatin was designed to circumvent mislocalization and misprocessing of Pt 
typically encountered when trying to track small molecules tethered to large, charged 
fluorophores. This chapter contains several proof-of-principle studies validating the use 
of this class of reagents for future purification and sequencing of Pt-bound nucleic acids. 
Chapter IV describes the first application of the click-capable Pt reagent technology: the 
demonstration of significant in-gel fluorescent detection of Pt-bound ribosomal RNA and 
transfer RNA extracted from picazoplatin-treated S. cerevisiae and the first evidence that 
cellular tRNA is a platinum substrate. Chapter V summarizes these data, which suggest a 
potential ribotoxic mechanism for cisplatin cytotoxicity and broadly describe a 
convenient click chemistry methodology that can be applied to identify other metal or 
covalent modification-based drug targets. 
This dissertation includes previously published and unpublished co-authored 
material.  
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CHAPTER I 
 
MOLECULAR MECHANISM OF PLATINUM (II) THERAPEUTICS 
 
Introduction and Recognition of the Contribution of Others in This Dissertation 
 The research described in this dissertation was performed in the laboratory of Dr. 
Victoria J. DeRose, as part of an effort to understand the diverse molecular mechanisms 
of platinum anticancer therapeutics. The projects described herein, specifically the 
concept of ribosomal RNA targeting by cisplatin, were co-developed and guided by Dr. 
DeRose with helpful input from fellow graduate students Dr. Erich G. Chapman, Dr. 
Alethia A. Hostetter, and Dr. W. Luke Ward. Chapter I outlines the discovery and history 
of Pt(II) drugs, and recent work suggesting that non-DNA targets, such as RNA, may 
play critical roles in cytotoxicity. This chapter contains excerpts from a co-authored 
review written in 2011 with Dr. Chapman, Dr. Hostetter, Amanda L. Miller, and Dr. 
DeRose.1 Chapter II recounts our investigation of the biochemical interactions of 
cisplatin in S. cerevisiae. This work was published in ACS Chemical Biology in 2012, 
comprises research performed by Dr. Hostetter and myself and was co-authored with Dr. 
Hostetter and Dr. DeRose.2 Chapter III reports on an exciting new technology conceived 
by Dr. DeRose and developed through my collaboration with Jonathan D. White and 
Alan D. Moghaddam (the self-titled “Captains of Click”). In this chapter, published in the 
Journal of the American Chemical Society in 2013, we have described the in vitro and in 
vivo applications for novel click-capable platinum complexes synthesized by Jonathan D. 
White with assistance from Lindsay E. Guzman.3 Chapter IV contains the major product 
of my graduate work, a comprehensive study of platinum adduct formation within the 
catalytic core of the S. cerevisiae ribosome. Dr. DeRose and I co-designed the 
experimental strategy and I performed the bench work. For these studies, I am very 
grateful to Jonathan D. White for providing reagents and to Rachael M. Cunningham for 
assisting with the in vivo experiments. This chapter comprises a manuscript co-authored 
with Jonathan D. White and Dr. DeRose that is being prepared for submission to PNAS. 
Finally, I would like to gratefully acknowledge co-workers in the Department of 
Chemistry and Biochemistry who have assisted with experimentation and provided 
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training, helpful discussion, and project guidance: Kory J. I. Plakos, Ruth B. Siboni, 
Devika S. Gates, Oggie Golub, and former mentored students Folashade Olwloro, 
Suzanne Mirashrafi, and Lindsay Guzman. 
 
Platinum Anticancer Drugs: Discovery and Early History 
 Cis-diamminedichloroplatinum (II), or cisplatin, is the flagship compound of a 
small class of FDA-approved platinum (II) anticancer therapeutics. Cisplatin was first 
synthesized by Michael Peyrone in 1844, but not recognized to have biological activity 
until the serendipitous discovery of its antiproliferative activity against E. coli in 1965 by 
Barnett Rosenberg and colleagues at Michigan State University.4,5 Interested in the 
potential for inorganic metal cancer therapeutics, Rosenberg led an effort to characterize 
the efficacy of cisplatin and derivatives in sarcoma- and leukemia-bearing mouse models. 
Shockingly, it was discovered that select cis platinum (II) complexes were capable of 
increasing the lifespan of treated animals by almost four-fold following a single injection 
at 8 mg/kg.6 Interestingly, the trans isomers were found to be clinically ineffective. In 
early preclinical trials, cisplatin toxicology was hampered by acute and chronic side 
effects including nephro-, oto-, and peripheral neurotoxocity.7 Alleviation of these 
symptoms through dose limitation, hydration, and combinatorial therapy allowed for 
FDA approval in 1978. These studies were the foundation of a discovery that would 
revolutionize cancer treatments; cisplatin therapy increased the cure rate of testicular 
cancer from 4% to over 90% in early detection cases, and is presently included in over 
half of cancer drug regimes.8  
 Structure-activity relationships have identified the approximate geometry and 
ligand set for optimal drug activity (such as cis conformation), but only two additional 
platinum therapeutic agents have been FDA approved since cisplatin in 1978 (Figure 
1.1). Carboplatin, cis-diammine-1,1’-cyclobutane-dicarboxylato-platinum(II), was 
patented in 1979 and FDA approved in 1989. This complex retains the cis-diammine 
configuration of cisplatin, but replaces the chloride leaving groups with a chelating 
dicarboxylate ligand designed to reduce its chemical reactivity and mediate oto- and 
nephrotoxicity. Oxaliplatin, (1R,2R-(N,N’-1,2-diamminocyclohexane)-(O,O’)-
ethanedioato)platinum(II), was FDA approved in 2002 and avoids issues with cross-
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resistance typically encountered with cisplatin and carboplatin. Figure 1.1 portrays 
several other platinum species already approved internationally but presently in U.S. 
preclinical trials, including picoplatin (U.S), nedaplatin (Japan), lobaplatin (China), and 
heptaplatin (South Korea).5 The underlying challenge faced by all these platinum 
therapeutics is acquired or intrinsic resistance, due in part to an incomplete 
comprehension of their intracellular localization and processing. The following chapter 
describes the current body of knowledge on the activity profile of platinum(II) 
therapeutics.  
 
Molecular Mechanism of Action 
 Early studies investigated the broad impact of cisplatin treatment on the synthesis 
of DNA, RNA, and proteins using isotopically labeled nucleotide or amino acid 
precursors. The major observation was selective inhibition of DNA synthesis, with a 
lesser effect on RNA and protein synthesis until higher intracellular concentrations of 
platinum were achieved.9 Another indication of DNA damage was the filamentous 
growth of E. coli observed upon cisplatin treatment, typical of DNA damaging agents 
such as UV and ionizing radiation.10 This led to an initial hypothesis that cisplatin was 
acting analogously to a subset of bifunctional alkylating agents containing two active 
chloride groups, such as chlorambucil, which crosslink genomic DNA and lead to 
replication stalling.6 Such bifunctional alkylating agents form interstrand crosslinks 
Figure 1.1. Structures of the three currently FDA approved platinum (II) therapeutics (1) 
cisplatin, (2) carboplatin and (3) oxaliplatin, as well as four newer complexes approved 
internationally that are currently or have recently gone through U.S. clinical trials: (4) 
picoplatin, (5) nedaplatin, (6) lobaplatin, and (7) heptaplatin. 
 
1 2 3 4 
5 6 7 
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between the N7 imino atoms of purine bases, across a distance of approximately 8 Å. 
However, this distance is on the periphery of the coordination sphere of an active cis 
platinum (II) isomer, and cisplatin was thus proposed to form intrastrand crosslinks on 
adjacent purine-N7’s, which span just ~3-5 Å in B-form DNA.11 Since the publication of 
this mechanistic theory in 1970, the majority of research has focused on platinum 
targeting of genomic DNA. It is commonly accepted that in DNA, intrastrand chelation 
induces structural distortions within the helix, which cause replication arrest and 
transcription inhibition, as well as secondary cell cycle arrest and DNA repair. The 
inability of DNA repair pathways such as nucleotide excision repair to remove Pt(II)-
containing nucleotides results in the activation of HMG family proteins, which trigger 
p53 to initiate an apoptotic signal (Figure 1.2).10 Although this theory describes one 
aspect of cisplatin cytotoxicity, it does not fully account for the properties of Pt(II) 
complexes that differentiate them from bifunctional alkylating species. The square-planar 
Pt(II) compounds represent a different class of metal-based complexes that have defined 
geometric ligand constraints, slow- to inert-ligand exchange, and binding that is 
influenced by kinetics rather than thermodynamics in most settings. Platinum complexes 
are soft Lewis acids, which preferentially react with biological targets containing nitrogen 
and sulfur donor ligands.1 Therefore, with a simplistic model, coordination chemistry 
Figure 1.2. Model of platinum drug binding within duplex DNA. B-form DNA duplex 
(light blue, purple) is conformationally restrained upon platinum adduct formation 
(orange). Failure of DNA repair pathways to excise the lesion results in high-mobility 
group (HMG, green) protein recruitment to the structural distortion. All images created in 
PyMOL using PDB files 2M2C, 3LPV, and 1CKT.  
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would predict that reactive platinum species would be rapidly sequestered by S-donor 
ligands in the plasma membrane and cytoplasm. This reactivity greatly expands the 
breadth of potential cytotoxic targets for this complex and warrants a thorough 
investigation of reactive partners encountered when first entering the cell, prior to nuclear 
translocation.   
 
Platinum Drug Cellular Uptake and Activation 
 In patients, cisplatin is administered intravenously in doses ranging from 50-120 
mg/m2.10 Following entry into the bloodstream, cisplatin is subject to relatively high 
chloride concentrations (100 mM), which suppress exchange of its two active chloride 
ligands. The same principle applies to carboplatin and oxaliplatin, allowing them to 
remain as inert dicarboxylate species. This mediates reactivity towards circulating 
proteins, although significant cisplatin accumulation on human albumin is observed 24 h 
post-treatment.7 Active transport of the neutral complex across the plasma membrane can 
occur via copper transporter 1 (Ctr1), copper transporter 2 (Ctr2), the P-type copper-
transporting ATPases (ATP7A and 7B), and organic cation transporter 2 (OCT2). 
Differential expression of these membrane-associated proteins regulates cisplatin 
translocation into different tissues.12  
 Following cellular uptake, cisplatin becomes intracellularly activated by aquation 
of one or both of its chloride ligands, forming either a mono- or diaquadiammine 
platinum(II) cation. The substitution of water with chloride as a leaving group confers a 
positive charge to the complex, increasing its reactivity. Pt(II) is subsequently able to 
form coordinate covalent bonds to nucleophilic centers of its bimolecular targets. In 
nucleic acids, in vitro studies reveal that activated cisplatin preferentially binds the 
accessible and reactive imidazole N7 atoms on proximal purine bases. This is especially 
true for studies using duplex nucleic acids where other potential Pt(II) ligands such as the 
N1 of adenine and N3 of cytosine are precluded from platinum binding by their 
participation in Watson-Crick base pairs.13 The major DNA adducts formed are 5’-
dGpdG-3’ 1,2-intrastrand adducts (47-50%), followed by 5’-dApdG-3’ 1,3-intrastrand 
adducts (23-28%), with platinum occasionally forming monofunctional adducts, 
interstrand crosslinks, or DNA-protein crosslinks (Figure 1.3).14 Other Pt(II) targets may 
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include mitochondrial DNA (which lack the nucleotide excision repair pathway)15, 
purine-N7’s of cytoplasmic RNA, nucleophilic amino acids such as histidine and 
cysteine, and thiol-containing small molecules such as glutathione. It is well 
acknowledged that cisplatin binds many species throughout the cytosol; the slow 
dissociation kinetics of the bis-chelating leaving groups on carboplatin and oxaliplatin 
were designed to result in latent activation and decreased reactivity towards non-DNA 
targets.10 
Cellular Pt (II) Drug Trafficking and Localization 
Characterizing the spatial distribution of Pt(II) binding within a cell provides 
critical information regarding the types of the cellular machines and architectures that
Pt(II) complexes may target. Major cellular targets, with regions important for RNA 
processes, are highlighted in Figure 1.4. Atomic absorption spectroscopy (AAS) and 
inductively coupled plasma mass spectroscopy (ICP-MS) have been utilized to quantify 
Pt drug accumulation in subcellular organelles. Nuclear accumulation, presumably from 
DNA binding, is observed for cisplatin and other Pt(II) therapeutics, in good agreement 
with predicted mechanistic theory.16 Although it is generally accepted that cisplatin-DNA 
adducts are responsible for the majority of a cell’s apoptotic response, studies in HeLa cells 
have proposed that 75-85% of the drug becomes covalently linked to protein, while only 1-5% 
of the drug actually reaches nuclear DNA.17 In our lab, we have directly quantified Pt(II) 
accumulation within yeast RNA and DNA using ICP-MS at therapeutically relevant 
concentrations of cisplatin, and have demonstrated there is 4-20% more accumulation of Pt in 
Figure 1.3. (Left) Purine nucleotides guanine and adenine, with N7 positions highlighted 
in red. (Right) Model of the major 5’-dGpG-3’ crosslink (white) observed following in 
vitro treatment of DNA with cisplatin. Figure created in PyMOL using PDB file 3LPV.  
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total RNA than DNA (further described in Chapter II).2 Cisplatin accumulation in intact 
mitochondria18 as well as drug binding to mitochondrial DNA have been quantified using 
AAS and by immunodetection techniques.19–21 More recently, Pt accumulation has been 
detected in vesicles by ICP-MS following the treatment of cells with cisplatin, 
carboplatin and oxaliplatin.22,23 The importance of vesicular Pt(II) accumulation is 
currently unknown, but may lend insight into biological processing of drug damaged 
biomolecules.  
 Direct imaging techniques have also provided a powerful means to study 
platinum distribution in treated cells. Fluorescently tagged platinum compounds are 
exceptionally useful for visualizing the cellular localization of platinum drugs in real 
time. These drug conjugates typically utilize the chelating ligand ethylenediamine (en) as 
an anchor for attaching labels such as fluorescein.24 The effects of attaching a large, non-
polar fluorophore on the biological distribution and processing of platinum drugs must be 
taken into account in interpreting these data. However, supporting biological assays show 
that while the Pt(II)-fluorophore conjugate is ~4-fold less potent that cisplatin, Pt(II)-
resistant cell lines are similarly insensitive to the two complexes suggesting that the 
complexes may be similarly processed in vivo.25 
Figure 1.4. Subcellular sites of platinum accumulation, listing the organelles that 
accumulate Pt drugs in cancerous cells and the locations of important RNA processes 
within the cell.   
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In one of the first studies of this type, Reedjik and coworkers used a 
carboxyfluorescein diacetate-tagged [Pt(en)Cl2] complex to monitor localization of the 
compound within human osteosarcoma cells. Initially diffuse throughout the cell, the 
Pt(II) complex accumulates in the nucleus after 1-2 hours and after 6-8 hours, the 
compound appears to migrate out of the nucleus and into Golgi bodies.26,27 In a human 
ovarian carcinoma cell line, a similar Pt(II)-fluorophore species can be tracked to the 
periphery of the cellular membrane, in the nucleus, and in small vesicular structures 
scattered throughout the cytoplasm.25 Fluorescent Pt(II) complexes have been used in 
concert with specific small molecule inhibitors to show that these compounds are first 
sequestered by lysosomes, subsequently transferred to Golgi apparatus and finally 
packaged into secretory vesicles.28 This approach of fluorescently tagging Pt drugs has 
produced, over several studies, a more uniform picture of Pt(II)-conjugate localization. 
Initially, cisplatin and other Pt(II) drugs enter the cell and accumulate to varying degrees 
in the vesicles and organelles of the cytoplasm, including lysosomes, Golgi, and 
mitochondria. From there Pt enters and accumulates in the nucleus, often accumulating 
along the periphery of the nucleus and in nucleoli. Depending on the treatment conditions 
and cell type this nuclear accumulation may become greater than cytoplasmic 
accumulation after 1-4 hours. Finally, export from the cell may involve the Golgi and 
vesicles of the secretory export pathway. However, in general, platinum distribution is 
highly variant throughout different cell lines and over different treatment conditions, 
highlighting the need for a uniform method for characterization of kinetically preferred 
species. In Chapter III, I describe our recent work using the click reaction to fluorescently 
post-label platinum bound species in vitro, demonstrating the potential for highly 
accurate and unbiased real time future Pt(II) tracking studies.3 
 
DNA-Pt(II) Binding Not Required for Cisplatin Cytotoxicity  
Importantly, alternative cellular pathways that execute apoptosis following 
cisplatin treatment have been identified. Recent studies in mammalian cells have 
exhibited rapid and nucleus-independent cytoplasmic initiation of cisplatin toxicity. In 
these studies, enucleated cytoplasts were treated with cisplatin, and probed for active 
(cleaved) caspase 3. Levels of cleaved caspase 3 were found to greatly increase relative 
 9 
to an untreated control.29,30 The signaling pathways responsible for initiating this 
apoptotic signal, and whether cytosolic RNA targets could be involved, are yet 
unexplored. These discoveries, in conjunction with the relatively long timescale of 
nuclear DNA accumulation (up to 4 hours), describe an undefined cytoplasmic initiator 
of cytotoxicity, which may very well be mediated by RNA damage. Therefore, this 
evidence premises our investigation into RNA as a potential target for platination in vivo, 
and its contribution to the antitumor activity of the drug. 
 
RNA: A Putative Therapeutic Target 
 RNA plays critical roles in the transfer of genetic information, protein synthesis, 
and signaling events.31 In addition, novel noncoding RNA species and their 
corresponding functional roles are continuously being discovered. Such findings include 
the discovery of siRNA, microRNA, piwi-interacting RNA, long noncoding RNAs, and 
most recently, competing endogenous RNAs (ceRNAs). This fascinating RNA-dependent 
RNA regulatory network centers around the concept that a myriad of different RNA 
species, including lncRNAs, pseudogenes, circular RNAs, and protein-encoding mRNAs, 
communicate with and co-regulate each other by competing for shared miRNAs.32 This 
intricate network of RNA interactions implies roles for RNA well beyond the normal 
scope of gene expression. 
Broadly, this functional range is due to rich structural diversity facilitated by 
intramolecular tertiary contacts and intermolecular interactions, which are defined by 
hydrogen bonding and electrostatics. A general description of the many stable structures 
accessed by RNA is provided in Figure 1.5a. Common motifs include hairpins, internal 
loops, bulged nucleotides, and 3-helix junctions. These secondary and tertiary structural 
facets enable recognition by other RNAs, proteins, and small molecules. For instance, the 
sarcin-ricin loop, a solvent exposed region of the large ribosomal RNA subunit, contains 
several unique RNA-specific structural motifs which enable its recognition and binding 
by translation factors (Figure 1.5b).33 Disruption of these interactions by ribotoxins such 
as α-sarcin and ricin results in rapid apoptotic signaling.34 
 RNA is a promising small molecule target, but when compared to nuclear DNA, 
there are relatively few complexes that target RNA with the specificity and affinity of 
 10 
those which intercalate DNA. Moreover, RNA-targeting small molecule therapies have 
been restricted due to insufficient exploration of the structural qualities of small 
molecules that target RNA, and conversely, the classes of RNA structures that can bind 
small molecules.35 However, the interactions of metal ions with RNA have been 
extensively investigated and are critical for RNA folding, structure, and biochemical 
activity. A significant number of RNAs adopt structures capable of hosting cationic metal 
ions, such as Mg2+, K+, and Na+. Only a fraction of the ions that are involved in RNA 
folding and catalysis can be deduced from crystal structures, and necessitate concurrent 
biochemical and biophysical studies.36 Cationic binding pockets predicted from 
molecular simulations based on NMR structural data within the sarcin-ricin loop37 are 
described in Figure 1.5b. These regions of high negative charge density are typically 
coordinated by a network of water molecules and metal ions, and make kinetically 
favorable platinum (II) binding targets, especially true for abundant cytoplasmic species 
such as ribosomal RNA. It is interesting to note that the repetitive structure of the DNA 
double helix may offer a limited number of potential Pt(II) coordination geometries. In 
contrast, RNA exhibits a diverse array of secondary and tertiary architectures, which 
include these specific and pre-organized metal-ion binding sites13,38,39 as well as solvent-
excluded folds where nucleobase pKa’s can be significantly altered from those observed 
in solution.40,41 Consequently, these structures greatly expand the chemical space in 
which physiological metal complexes could find appropriate binding pockets. The limited 
collection of studies describing known Pt(II) lesions on isolated RNA are outlined below. 
 
RNA-Pt(II) Lesions: In Vitro Molecular Investigations 
 Seeking to understand how cisplatin may target RNA structures on a molecular 
scale, a handful of recent studies have described the formation of Pt(II) adducts within 
isolated RNAs. These studies examine cases ranging from the platination of relatively 
short single-stranded RNAs42 to studies involving coordination of cisplatin to 
ribosomes.2,43 In accordance with the observations above, an emerging feature of these 
studies seems to be ability of Pt(II) complexes to bind in non-Watson-Crick base paired 
regions of RNA.  
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Several labs showed a keen interest in characterizing platinum lesions within 
isolated transfer RNAs. Following incubation with activated cisplatin, Pt(II) adducts 
formed within the purine-rich acceptor stem and anticodon loop of purified tRNAPhe and 
tRNAAla.44,45 However, these adducts were very dependent on sequence; conversion of a 
GU wobble pair to a canonical GC base pair in the tRNA stem precluded platinum 
Figure 1.5. (a) Common secondary structures accessed by cellular RNA, including 
hairpins, single-stranded regions, single and multi-nucleotide bulges, three and four-helix 
junctions, and symmetric or asymmetric loops. (b) S. cerevisiae sarcin-ricin loop 
ribosomal RNA, a distorted hairpin with several RNA-specific structural motifs including 
a GAGA tetraloop, a bulged-G motif, and an S turn. These features facilitate recognition 
by a variety of protein co-factors, including the ribotoxins α-sarcin and ricin. Nucleotides 
predicted by molecular simulations to host cation binding pockets37 are indicated by 
“M2+”. 
 
(a) 
(b) 
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binding in that region.  Cisplatin has also been used as a chemical probe for identifying 
solvent exposed purine nucleotides in intact bacterial ribosomes.43 Stable platinum 
adducts formed within helix 24 of E. coli ribosomes were identified by primer extension 
as stop sites caused by platination. Using this method, it was found that G nucleotides in 
several non-Watson-Crick base-paired regions of the RNA were targeted by cisplatin. 
This targeting provides another example of platinum coordination within regions of 
complex RNA structure, notably even in the presence of competing GG sequences in 
duplex regions of the same RNA. Chapter IV describes additional instances of Pt(II) 
binding within the catalytic core of the S. cerevisiae ribosome, specifically throughout the 
sarcin-ricin loop. More recently, the processing, stability, and silencing capacity of 
cisplatin-modified siRNA and miRNA were investigated in vitro. Pt(II) lesions enhanced 
the stability of the biologically active antisense strand to nuclease degradation. However, 
metalation severely reduced the silencing capacity of these RNAs in a luciferase assay.46  
Interestingly, platination of the sense strand does not appear to adversely affect early 
siRNA processing.47 
 In our lab, Erich Chapman and Alethia Hostetter have characterized cisplatin 
binding within a 41nt RNA subdomain (the ‘branch-bulge domain’) of the U2-U6 snRNA 
complex, part of the catalytic core of the spliceosome. This BBD RNA consists of a 
hairpin structure in which base paired regions flank a purine-rich, asymmetric internal 
loop. Reaction of this RNA with an aquated form of cisplatin resulted in a novel GpG Pt-
induced intramolecular crosslink, which was confirmed by alkali hydrolysis mapping.48 
While the structure of this RNA is currently unknown, the nucleotides involved in this 
crosslink have been proposed as metal ion binding sites in the full U2-U6 snRNA 
complex.49,50 In light of this information, it is intriguing to speculate that cisplatin may 
compete with native metal ion binding sites in RNA. This type of mimicry would be 
particularly interesting as metal ions often mediate important tertiary contacts between 
interacting RNA domains51 where crosslinking could potentially disrupt the dynamic 
function of these structures. Although many similar instances of RNA-Pt adduct 
formation have been reported, the link between specific Pt(II) lesions and downstream 
functional consequences is still unclear. In the next section, the broad impact of cisplatin 
on RNA-dependent cellular processes is described. 
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Influence of Pt on RNA-Based Processes 
 RNA-based processes in cells are influenced by treatment with Pt(II) compounds 
(Figure 1.6). Each of these processes depends heavily on complex RNA structures as 
well as on RNA-protein and protein-protein interactions.  With the exception of carefully 
designed RNA polymerase experiments in which a single Pt(II) adduct is specifically 
placed within a DNA template,52,53 the studies in Figure 1.6 have been conducted in a 
heterogeneous environment where platination may interfere in many possible ways. Pt(II) 
adducts formed with RNA or DNA templates, RNA products, or ribonucleoprotein 
complexes all have the potential to disrupt these RNA-dependent processes. 
Platinum interference has been implicated in almost every step of the RNA 
lifecycle, from transcription of pre-mRNA to translation of mature mRNAs into 
functional proteins. Cisplatin has been observed to preferentially block transcription of 
ribosomal RNA in HeLa cells and drug treatment results in a redistribution of the RNA 
Figure 1.6. Incidences of stable RNA-Pt adducts and disruption of RNA-based cellular 
processes by cisplatin, including inhibition of the following processes: (a) nucleolar 
rRNA transcription, (b) pre-mRNA splicing, (c,-e) mRNA translation, following either 
mRNA or cell extract pre-treatment with Pt(II), (f) siRNA and miRNA silencing capacity 
in cell culture.  
rRNA 
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polymerase I transcription machinery.53 In mammalian cells, arrest of RNA polymerase II 
at a platinum-DNA lesion has been demonstrated in vitro,54 in cellular extracts,52 and 
recently, in vivo.55 The structural basis for this inhibition has also been reported, in which 
it was found that transcriptional inhibition was a result of the inability of the DNA lesion 
to enter the active site of the enzyme. Interestingly, this mechanism of polymerase 
stalling is unique from that of similar DNA lesions that occur upon UV irradiation.56   
Splicing is a critical step in the RNA lifecycle and is responsible for the 
successful maturation of pre-mRNA transcripts. In HeLa cell nuclear extract, a dose-
dependent inhibition of pre-mRNA splicing was observed after treatment with tetraplatin  
(tetrachloro[d,l-trans]1,2-diaminocyclohexane platinum(IV) and cisplatin. The inhibition 
of splicing observed in these experiments can be correlated to a disruption in formation of 
spliceosomal complexes on pre-mRNA.57 An inhibition of splicing has also been 
observed following cisplatin treatment of the protein-independent self-splicing 
Tetrahymena rRNA, possibly through the formation of interstrand cisplatin-RNA 
crosslinks.58  
Efficient translation is highly dependent on intact and functional RNA molecules 
such as ribosomes, messenger RNA, and tRNA. Platinum disruption of translation has 
been described to a great extent in cellulo in rabbit reticulocyte lysate. Early studies by 
Rosenberg and Sato demonstrated that Pt(II)-bound mRNA added to platinum-free 
cellular lysate inhibits protein synthesis by 85%, while Pt(II)-incubated lysate treated 
with platinum-free mRNA showed a 19% decrease in translation.59 In a later study, it was 
found that the rate of translational inhibition by cisplatin matched that of NaF, an 
inhibitor of translational initiation. In addition, the polysome profiles of both cisplatin 
and NaF showed an apparent decrease in polysome intensity.60 This was interpreted to 
mean that cisplatin disrupted translation by preventing initiation. Heminger and 
coworkers later revisited this study and noted a slightly different result, in which the 
steady accumulation of higher order polysomes was observed on mRNA templates 
following Pt(II) treatment.61 They concluded that their data showed Pt(II) inhibition of 
elongation, not initiation. However, despite the appearance of higher-order polysomes, 
the apparent intensity of the polysome fractions decreases upon Pt(II) treatment in both 
studies in conjunction with an increase in the population of free ribosomes. Therefore, it 
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is likely that platinum interferes in both the initiation and the elongation of ribosomes in 
cellulo to cause an overall decrease in protein synthesis. 
Recent work has documented specific platinum binding events within the 
translation machinery. As mentioned previously, stable cisplatin adducts have been 
mapped to various locations within E. coli and S. cerevisiae ribosomal RNA through 
primer extension of RNA extracted from treated cells.2,43 The effects of platinum binding 
in these locations on overall protein synthesis have not been investigated.  
 
Cellular Response to Damaged RNAs and Initiation of Stress Responses 
There is a growing literature on the sophisticated mechanisms of RNA 
surveillance, repair and damage control.62 Nonfunctional mRNA surveillance is 
reasonably well-studied, and can proceed via nonsense mediated decay, nonstop mediated 
decay, and no-go decay.63 The TRAMP complex mediates errors in ribosome biogenesis 
by tagging nonfunctional and defective rRNAs for exonucleolytic degradation.64 Other 
defined RNA degradation pathways include noncoding RNA decay62, nonfunctional 
ribosome decay65, and rapid tRNA decay66. 
In some cases, damaged RNA molecules can be repaired. Instances of RNA repair 
appear to be best understood within the context of a viral or bacteriophage response to 
host immune cleavage of transfer RNA, an innate mechanism to prevent the spread of 
infection.  Cellular stresses such as amino acid deprivation can also trigger transfer RNA 
cleavage within the anticodon loop. Following 3’ and 5’ end-remodeling by RNA editing 
enzymes, tRNA ligases recognize and re-anneal the cleaved ends (typically 3’-OH and 
5’-PO4).67,68 RNA repair is also described for the 3’ ends of positive-strand viral RNAs 
subjected to exonucleolytic cleavage by host RNases.69 There is only one known class of 
enzymes, the AlkB family, capable of repairing base alkylation by small molecules. 
Methyl methanesulfonate-induced lesions on mRNA and tRNA, specifically 1-
methyladenine and 3-methylcytosine, inhibit translation in vitro but can be rescued by 
treatment with human AlkB.70 During methyl methanesulfonate treatment in AlkB-
deficient E. coli, 10-fold more lesions were repaired in RNA than DNA. This activity was 
predominant in RNAs less than 200 nt (mainly tRNAs).71 
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 Recently, researchers have illuminated a link between specific incidences of 
cellular RNA damage and the induction of apoptosis in vivo. Aberrant RNA cleavage 
events that cause disruption of RNA-protein interactions have been linked to early 
disease progression and programmed cell death, suggesting the potential for a global 
cellular response to small RNA structural modifications.72–74 Onconase, a cytotoxic 
ribonuclease, initiates apoptosis through tRNA cleavage and is currently being harnessed 
for chemotherapeutic purposes.75 The specific mechanistic pathway for this activity is not 
known, but it is speculated that onconase-mediated tRNA cleavage directly activates 
cytochrome c, an effector of apoptotic signaling. Ribotoxic damage to the sarcin-ricin 
ribosomal RNA loop (Figure 1.5b) by ricin and α-sarcin results in the rapid onset of an 
apoptotic signal. Ricin depurinates the adenine at position 2660 and α-sarcin irreversibly 
hydrolyzes the bond between the two adjacent purines at the terminal helix loop. These 
modifications cause structural distortions that prevent recognition by the elongation 
factor eEF2.  Inhibition of eEF2 binding inhibits protein synthesis and initiates an 
apoptotic signal.34 The mechanism by which rRNA damage is sensed is not fully 
understood, but it is clear that the structural integrity of this loop is essential for 
translation and cell viability. In Chapters II and IV, I describe Pt(II) lesions within 
ribosomal RNA, specifically within the sarcin-ricin loop itself, which may be sufficient to 
initiate apoptotic signaling.  
 
Summary of Chapter I and Bridge to Chapter II 
 In this chapter, I have described the history of platinum anticancer therapeutics 
and the current body of knowledge regarding the cellular uptake, activation, distribution, 
and processing of cisplatin. I have summarized the predominant view of the importance 
of nuclear DNA targeting by this complex and provided strong evidence for RNA as a 
potent alternative Pt(II) target. In Chapter II, entitled “RNA-Pt (II) Adducts Following 
Cisplatin Treatment of Saccharomyces Cerevisiae”, we perform a thorough assessment of 
RNA-Pt species in vivo. The impact of cisplatin in S. cerevisiae is measured using growth 
curves, clonogenic assays, and tests for apoptotic markers. Pt(II) lesions are quantified 
and characterized in DNA and RNA using ICP-MS, and cisplatin adduct formation 
within ribosomal RNA is mapped to nucleotide resolution.  
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CHAPTER II 
 
RNA-PT(II) ADDUCTS FOLLOWING CISPLATIN TREATMENT OF 
SACCHAROMYCES CEREVISIAE 
 
 This chapter contains important contributions from Alethia A. Hostetter and Dr. 
Victoria J. DeRose. A.A.H. performed the ICP-MS experiments, the growth and 
clonogenic assays, the DAPI and TUNEL staining. I performed the rRNA mapping 
experiments. A.A.H. and I co-wrote the manuscript. V.J.D. guided the project and 
provided significant editorial feedback. This chapter includes work published in ACS 
Chemical Biology (2012, 7, 218-25, © 2013 American Chemical Society). 
 
RNA as a Drug Target 
 As a modulator of gene expression at multiple levels, RNA is an important 
potential drug target (1–5). In addition to the well-defined functions of mRNA, tRNA, 
and rRNA, novel regulatory roles are continuously being defined in both transcription 
and translation (1, 6). Such findings include the discovery of siRNA, microRNA, piwi-
interacting RNA, and long noncoding RNAs. Moreover, RNA damage and RNA-protein 
interactions have been linked to early events in disease and to programmed cell death (7-
10). RNA targeting by small molecule interactions has the potential to influence these 
cellular pathways through both specific and nonspecific mechanisms.  
While drug-RNA interactions have the potential to impact cell fate by disrupting 
RNA regulatory pathways, a challenging aspect for this field is assessing RNA-drug 
interactions and RNA accessibility in vivo. For this purpose, a covalent RNA-drug adduct 
is of value in quantifying target binding and following the fate of the targeted RNA. The 
inertness of metal-RNA adducts formed following treatment with Pt(II) anticancer drugs 
provides one method of monitoring small-molecule distribution on cellular RNA. 
Cisplatin (cis-diamminedichloridoplatinum(II)) is a potent antitumor agent that has had a 
particularly major clinical impact on the treatment of testicular and ovarian cancers. 
Currently, cisplatin and the structurally related carboplatin and oxaliplatin are used in the 
treatment regimes of 50-70% of cancer patients (11). In vivo, cisplatin-derived Pt(II) 
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species form kinetically inert ‘covalent’ adducts with biomolecule targets (12, 13). Drug 
binding to adjacent purines on genomic DNA has been linked to cell cycle arrest at the 
G2 phase and the induction of programmed cell death, one foundation of antitumor 
activity (14). Non-genomic contributions to cisplatin’s therapeutic action are also under 
active investigation. In particular, cisplatin treatment can disrupt RNA-based processes 
such as splicing and translation (15-17). Targeting of non-DNA species, including RNA, 
by cisplatin may contribute to or sensitize a cell to the downstream effects of this drug, 
including the induction of apoptosis.  
The distribution of Pt in different RNA species has not been previously 
determined in cellulo in eukaryotes. Here, we use Saccharomyces cerevisiae for in cellulo 
analysis of Pt adduct formation on mRNA, rRNA, and total RNA and DNA. S. cerevisiae 
was selected as a model and has been used previously for drug studies due to the high 
level of conservation between mammalian and yeast cellular processes, including 
components of cell-cycle regulation and mRNA turnover (18,19). We report the action of 
cisplatin on S. cerevisiae in minimal media based on growth curves, clonogenic assays, 
and tests for apoptotic markers. Despite high cytotoxicity, under the conditions studied 
cisplatin does not induce apoptosis. Estimated in-cell Pt concentrations and platinum 
accumulation on mRNA, rRNA, total RNA, and DNA were determined using inductively 
coupled plasma mass spectrometry (ICP-MS). Interestingly, while similar Pt 
accumulation was observed on rRNA and total RNA, significantly less accumulated on 
mRNA. Mapping by reverse transcription demonstrated specific Pt adduct formation on 
rRNA sequences conserved between yeast and humans. Taken together, these data 
highlight important differences in the relative accumulation of Pt on different RNA 
species and provide insight into the accessibility of cellular RNA to small, cationic 
molecules. 
 
Cisplatin Treatment Causes Acute Cell Death  
S. cerevisiae has been used previously to investigate cisplatin toxicity, including drug 
transport, DNA repair, and the genes involved in drug resistance and sensitivity (20-22). 
Within these reports, however, the sensitivity of S. cerevisiae to cisplatin treatment varies 
widely. In addition, although cisplatin causes apoptosis in mammalian systems (23), this 
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topic had not been addressed for S. cerevisiae despite a growing body of work on yeast 
apoptotic-like cell death pathways (24,25). Therefore, we established cisplatin 
cytotoxicity in S. cerevisiae (strain BY4741) by growth and survival curves as well as 
with apoptotic markers .  
Cisplatin is activated by hydrolysis of the labile chlorido ligands, which in 
patients occurs upon exposure to relatively low intracellular [Cl–] (26). For cultured cells, 
however, significant cisplatin aquation may take place in the media. In rich media such as 
YEPD (yeast extract peptone dextrose), the highly reactive aquation products may 
interact with soft sulfur- and nitrogen-containing nucleophiles to effectively sequester the 
drug, which could be one reason for higher IC50 measurements than those observed in 
mammalian and cancer cell lines (e.g. 500 µM  in S. cerevisiae in YEPD media (27) 
Figure 2.1. Cisplatin inhibits yeast growth and viability. (a) Exponential growth curves 
of BY4741 S. cerevisiae continuously treated with 0, 100, and 200 µM cisplatin in SD 
media. (b) Viability of cisplatin-treated yeast plated onto drug-free media,. Results 
presented as the means ± standard deviation from four (a) and three (b) independent 
experiments.  
 
(a) 
 
(b) 
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versus 2–40 µM  for human cancer cell lines (28-30)). In Figure 2.1, we assayed drug 
toxicity in minimal SD (synthetic dextrose) liquid media (Figure 2.1a), and found a 
moderate (76 ± 8%) and severe (36 ± 1%) reduction in culture density at saturation for 
100 and 200 µM  drug, respectively. The effect of cisplatin on the viability of BY4741 
cells, monitored by clonogenic assay (Figure 2.1b), shows a marked decrease in the 
number of dividing cells that begins after just 1–2 h incubation in the drug. The majority 
of irreversible cisplatin toxicity coincides with the onset of exponential growth that is 
observed in Figure 2.1a. We therefore chose 6 h (Table 2.1) as a relevant timepoint to 
investigate the distribution of cisplatin-derived Pt species on different RNAs within the 
cell.  
 
 
 
 
 
 
 
 
 
aMeasured at 6 h relative to control. 
 
Cell Death Is Not Apoptotic  
 Cell death via apoptotic pathways has been reported for S. cerevisiae treated with 
several agents including anticancer drugs such as bleomycin and valproate, but has not 
been reported for metallodrugs such as cisplatin (24,25). We assayed cell cultures for 
hallmarks of apoptosis after continuous treatment with cisplatin for 6–12 h. Similar to 
mammalian systems, yeast apoptosis results in chromatin condensation and DNA 
fragmentation (31). DAPI DNA staining of BY4741 cells in 200 µM cisplatin at 6 h 
treatment showed significant differences from the control in chromatin morphology 
(Figure 2.2a). In almost all samples, nuclei were either fragmented and diffuse, or 
abnormally enlarged. These findings are consistent with an activation of apoptosis or an 
alternative programmed death pathway. Cell cycle arrest, previously reported in cisplatin-
treated yeast and mammalian cultures (32, 33) was observed with an increase in both 
parent cell and bud size. Such examples of oncosis are generally associated with necrotic 
Table 2.1. Cisplatin influence on S. cerevisiae  
           [Cisplatin] 
  100 µM 200 µM 
Culture Densitya 87 ± 6% 71 ± 12% 
Cell Viabilitya 58 ± 5% 27 ± 8% 
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cell death (34), with some exceptions (35), and contrast with the reductions in cell sizes 
generally observed from slow cell division due to metabolic factors (36). 
Apoptosis was further assayed through terminal dUTP nick-end labeling 
(TUNEL) (31), to detect cleaved DNA. Despite disruptions in cell and chromatin 
morphology, cells were TUNEL-negative following treatment with 200 µM cisplatin for 
both 6 h (Figure 2.2b) and 12 h (data not shown). This suggests that under these 
conditions, cisplatin treatment disrupts normal chromatin segregation but is insufficient 
to initiate an apoptotic signal culminating in double-stranded DNA breaks.   
The majority of yeast apoptosis pathways are mediated by YCA1, a type 1 
metacaspase, or by AIF1, a homolog of mammalian apoptosis-inducing factor (24, 31). 
To determine if cisplatin-induced toxicity involves either of these pathways, we assessed 
cell viability in YCA1 and AIF1 deletion mutants treated with 200 µM  cisplatin for 6 h. 
For both ΔYCA1 and ΔAIF1, no differences in cell viability were observed, indicating 
that neither protein is mediating cytotoxicity in yeast (Figure 2.2c). In summary, 
cisplatin-treated S. cerevisiae are undergoing a non-apoptotic form of cell death, but 
whether it is uncontrolled necrosis, a programmed necrosis, or alternate form of cell 
death cannot be determined by the present data (35).   
Other antitumor agents including the DNA fragmenting bleomycin and the 
microtubule directed paclitaxel, as well as the ribosome targeting toxin ricin, appear to 
induce apoptotic markers in yeast (25, 37). From several reports, a stimulus can induce 
yeast apoptosis at low doses and necrosis at high doses (36,38). It is therefore plausible 
that cisplatin induces yeast apoptosis in a different treatment window than used here.  It is 
also possible that, unlike the case for other toxins, yeast lacks a key component of a 
pathway through which cisplatin treatment triggers apoptosis. One candidate is the tumor 
suppressor p53, which has no yeast homologue (21). Significantly, mismatch repair 
pathways have been linked to p53-driven apoptosis in mammalian cell lines, while 
deletion of parallel MMR components in yeast does not influence cisplatin sensitivity 
(39). In mice, it has been demonstrated that cell cycle arrest occurs in a p53-independent 
manner, despite its requirement for the initiation of apoptosis (40). Thus, p53-
independent cisplatin-induced cell toxicity pathways appear to be present that in yeast 
result in acute cell cycle arrest and disrupt chromatin morphologies, but not the hallmark 
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DNA cleavage events associated with apoptosis. Similar phenotypes have been observed 
in S. cerevisiae following treatment with tunicamycin, an X-type agent that also causes 
cell-cycle arrest and the unfolded protein response, but death by non-apoptotic methods 
(41).  
 
Intracellular Pt Concentrations  
 The concentration of Pt species inside a cell following cisplatin treatment is 
affected by a complex set of dynamics including passive diffusion, active transport, and 
active efflux from the cell (21,26). To assess intracellular Pt levels, the accumulation of 
Pt in whole yeast cells was measured by ICP-MS (Figure A.1, Appendix A). Values of 
5.0 ± 0.6 × 106 and 2.1 ± 0.1 × 107  Pt/cell for 100 µM  and 200 µM  cisplatin treatment 
after 12 h reflect previous results of 7-30 × 106 Pt/cell for yeast incubated with 130 µM  
Figure 2.2. Tests for apoptotic markers. (a) DAPI staining of yeast treated with 0 and 200 
µM cisplatin for 6 h. (b) TUNEL assay of yeast treated with 0 and 200 µM cisplatin for 6 
h, +/- 5 U DNase I. (c) Viability of BY4741, ΔAif1 and ΔYca1 treated with 200 µM 
cisplatin for 6 h, Inset: average cfu for control and cisplatin-treated cultures. Results 
presented as means ± standard deviation from three independent experiments. 
 
(a) 
(b) 
(c) 
BY4741  ΔAif1 ΔYca1 
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cisplatin for 18 h (42,43) and are in line with values for cisplatin-treated HeLa cells when 
differences in cell volume are taken into account (30,44).  
The increased volumes of cisplatin-treated yeast cells were estimated for 
calculating intracellular Pt concentrations (Methods). An average volume of (~40 fL) is 
calculated for untreated yeast, consistent with previous measurements (34,45). The 
average size of 200 µM cisplatin-treated yeast continuously increases, while that of 100 
µM cisplatin-treated yeast is consistent after 6 h, potentially reflecting differences in cell 
viability between these two treatment conditions at extended time points (Figure 2.3a).  
The resulting calculated in-cell Pt concentrations (Figure 2.3b) are 47 ± 10 and 84 ± 5 
µM measured at 6 h for 100 and 200 µM cisplatin, respectively. At 12 h the in-cell Pt 
concentration exceeds the concentration of cisplatin in the media. This effect, observed 
Figure 2.3. Estimated cell volumes and in-cell Pt concentrations. (a) Average estimated 
cell volumes following treatment with 100 µM  and 200 µM  cisplatin (see Methods). (b) 
Calculated in-cell Pt concentrations based on Pt/cell ICP-MS measurements and the 
average estimated cell volumes. Results averaged from at least three independent 
experiments presented as means ± standard deviation. 
 
(a) 
(b) 
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previously for other anticancer metallodrugs (46), is consistent with both an active 
transport process (47) and the fact that these drugs produce kinetically inert adducts with 
cellular targets, placing drug binding under kinetic rather than thermodynamic control 
(48).  
 
Pt Accumulation in Different Nucleic Acids  
 To lend insight into the exposure of cellular RNAs to intracellular Pt species, Pt 
adduct formation on total RNA extracted from cisplatin-treated yeast was quantified with 
ICP-MS. An exponential increase in Pt-RNA content was observed in parallel with the 
exponential increase in cellular Pt concentrations (Figure 2.4a), indicating that 
accumulation of Pt in RNA is proportional to whole-cell Pt accumulation. At 6 h, Pt 
accumulation corresponds to one Pt every 14,600 ± 1,500 and 5760 ± 580 nt for 100 and 
200 µM cisplatin, respectively. For perspective, the yeast ribosome is roughly 5600 nt 
(49).  
A comparison of Pt accumulation on whole-cell RNA and DNA, performed 
following 12 h treatment with cisplatin (Materials and Methods, Appendix A), yields ~ 
3-fold more Pt bound to DNA than RNA on a per nucleotide basis (Figure 2.4b). 
Cellular distribution studies performed in human cell lines have observed an 
accumulation of cisplatin-derived Pt in the nucleus and nucleolus (50), consistent with 
the higher density of Pt on DNA. However, there is 10–50 fold more RNA in a yeast cell 
than DNA (51,52), resulting in ~4–20 fold more Pt accumulation in the total cellular 
RNA than in the total cellular DNA (Table 2.2).  
Pt accumulation on poly(A)-mRNA and rRNA was compared in total cellular 
RNA harvested from yeast after 6 h of continuous cisplatin treatment. Poly(A)-messenger 
RNA was extracted with an mRNA Miniprep Kit while intact 25S and 18S rRNA were 
isolated by gel purification (Materials and Methods, Appendix A). Pt accumulation on 
rRNA is similar to that of total RNA on a per nucleotide basis, while significantly less 
accumulation per nucleotide is observed on poly(A)-mRNA (Figure 2.4c and Table A.1, 
Appendix A). Given that yeast RNA is 80% ribosomes, 15% tRNA, and 5% mRNA (51), 
it appears that Pt measured in total RNA is largely due to accumulation on ribosomal 
RNA. Assuming a statistical distribution of Pt adducts, these data indicate an average of 1 
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and 2 Pt adduct for every 3 ribosomes following 6 h treatments with 100 and 200 µM 
cisplatin, respectively. 
In yeast, global protein synthesis is dramatically reduced as early as 2-4 hr post-
cisplatin treatment, indicating a compromised translation machine, which may be a result 
of mRNA, tRNA, or rRNA modifications (27). In general, cationic aquated Pt species are 
expected to associate more readily with accessible sites in higher-order RNA structures, 
Figure 2.4. Pt accumulation per nucleotide in total RNA, DNA, rRNA, and mRNA. (a) 
Total RNA from yeast treated with cisplatin. (b) Total RNA and genomic DNA at 12 h 
treatment. (c) mRNA, total RNA, and rRNA at 6 h. Data values provided in 
Supplementary Table S1, and presented as means ± standard deviation for at least three 
independent experiments. 
(a) 
(b) 
(c) 
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which present a larger electrostatic driving force (50). The enrichment of Pt on rRNA 
relative to poly(A)-mRNA (Figure 2.4c) may be due to the high negative charge density 
of the ribosome and may present a contributing factor to cisplatin’s cytotoxicity, although 
the probability of Pt adducts associating with higher-order regulatory structures amidst 
otherwise single-stranded regions of cellular mRNAs is yet unknown. Additional factors 
that remain to be determined include the influence of Pt-RNA adducts on mRNA 
surveillance pathways and message turnover (53). 
 
Table 2.2. Estimated Pt atoms accumulated in the total RNA or DNA of one yeast 
cella 
                      [Cisplatin] 
  100 µM 200 µM 
DNA (104) 2  6 
RNA (104) 7–34 24–120 
aCalculation based on the mass of DNA and RNA in one haploid S. cerevisiae cell (60)  
 
Platinum Adduct Identification on rRNA  
 Specific locations of platinum adducts within S. cerevisiae ribosomal RNA were 
probed by RT primer extension, which stalls 3’ to adduct sites (54-56). Pt adducts may 
reflect the solvent accessibility and electrostatic potential of specific rRNA motifs. Using 
similar methods to probe for potential antibiotic sites, Rijal and Chow reported major 
platination sites within helix 24 of the E. coli small ribosomal subunit (56), revealing a 
significant RT stall at U801 that reflects Pt binding to adjacent guanines at positions 799 
and 800 (Figure 2.5). Secondary binding was observed at A792, suggesting the 
formation of a 3’-GA-5’ adduct between G791 and A790. As an ideal antibiotic drug 
differentially targets bacterial and eukaryotic ribosomes, we compared platinum adducts 
in this region (helix 18 in S. cerevisiae), which is located in close proximity to the 
peptidyltransferase center (Figure A.2, Appendix A) and fully conserved between yeast 
and humans but not E. coli (Figure 2.5).  
Primer extension was performed on total RNA extracted from yeast cultures 
treated with 0–150 µM cisplatin for 6 h. Figure 2.5 shows a dosage-dependant increase 
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in termination intensity at several positions, predicting sites of platinum binding. 
Significant platinum adduct formation occurs at the purine-rich capping loop of helix 18, 
as evidenced by two major stops in the sequencing gel at positions A792 (***) and A790 
(***) (Figure 2.5). Minor stalling is observed at A802 and G786. An additional minor 
stop site occurs directly on purine residue G797. This particular guanine lies 3’ to a 2’O-
methylated cytosine residue, which is known to pause primer extension under certain 
conditions (62). Alternatively, stalling at this site may be the result of an interstrand 
crosslink between G797 and G786, whose N7 atoms are stacked favorably for such an 
interaction (Figure 2.5).  
Certain RNA sites are expected to be more accessible and/or reactive. To detect 
early Pt accumulation on rRNA, helix 18 was probed after exposure to 100 µM cisplatin 
for 0, 1 and 3 h (Figure A.3, Appendix A). As expected, platinum targets the same 
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(***) and minor (*) Pt binding sites. Dideoxy sequencing ladders denoted by U, A, G, and 
C. Experimental results are summarized on secondary structure of the S. cerevisiae helix 18 
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purine residues as observed following 6 h treatment (Figure 2.5), showing transcription 
stops at positions A790 and A792 within the capping loop as early as 1 h post exposure to 
drug (Figure A.3, Appendix A). Stalling at A802 appears stronger at early timepoints, 
although its signal is minor in comparison to banding patterns observed within the 
terminal loop (A792 and A790) after 6 h cisplatin treatment. Importantly, at all 
timepoints, the reversal of the G783-C799 basepair in yeast and humans, which removes 
the preferred G799-G800 Pt binding site observed in E. coli, is sufficient to preclude Pt 
binding to G800 in yeast. Instead, binding within the stem is diverted to residue A802. 
These findings demonstrate that although aquated cisplatin products are highly reactive, 
they are remarkably sequence-specific in the context of complex RNA structures.  
 
Conclusions 
In this study, the ability of the anticancer drug cisplatin to form stable adducts 
with RNA was used to assess accumulation of Pt species on cellular RNA following drug 
treatment. Under the conditions of this study cisplatin toxicity was characterized by 
irreversible inhibition of cell division, but not apoptotic cell death. This suggests that in 
comparison with mammalian systems, a mediator of cisplatin-induced apoptotic 
pathways, such as p53, is lacking in S. cerevisiae. Comparison of Pt accumulation in 
RNA and DNA at 12 h shows ~4–20 fold more Pt accumulation in the total cellular RNA 
than in genomic DNA. Intact 25S and 18S ribosomal RNA accumulates the majority of 
cellular Pt, while significantly less accumulates on poly(A)-mRNA when compared on a 
per-nucleotide basis. Mapping by reverse transcription demonstrates that specific Pt 
adducts in eukaryotic ribosomes form in a dose- and time-dependent fashion, 
accumulating after just 1 h of treatment. Taken together, these data show significant 
accumulation of Pt adducts in eukaryotic RNA following treatment in cellulo with 
cisplatin, with significantly larger amounts of irreversible Pt-RNA adducts accumulating 
in ribosomal RNA as compared to mRNA, and a demonstrated specificity for particular 
binding sites in the eukaryotic ribosome. The results from these data emphasize potential 
for rapid and specific accumulation of small molecules on cellular RNA. The potential of 
such interactions to impact complex RNA regulatory pathways is of great interest.    
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Bridge to Chapter III 
 In Chapter II, we assessed the impact of cisplatin treatment on S. cerevisiae and 
quantified accumulation of Pt(II) on nucleic acids following drug treatment, discovering 
that 4-20 fold more Pt(II) accumulates on cellular RNA than DNA and identifying the 
ribosome as a cellular Pt sponge. In Chapter III, we describe a new click-chemistry based 
methodology for high-throughput analysis of Pt-bound species in cellulo.  
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CHAPTER III 
 
PICAZOPLATIN, AN AZIDE-CONTAINING PLATINUM (II) DERIVATIVE 
FOR TARGET ANALYSIS BY CLICK CHEMISTRY 
 
 This chapter contains contributions from Jonathan D. White, Alan D. 
Moghaddam, Lindsay E. Guzman, Dr. Victoria J. DeRose, and Dr. Michael M. Haley. 
V.J.D. and M.M.H. initiated the development of click-enabled Pt(II) compounds for this 
research. J.D.W., with direction from V.J.D. and M.M.H and assistance from L.E.G., was 
responsible for the synthesis and characterization of novel azide-modified Pt(II) reagents 
and corresponding alkyne-containing fluorophores. A.D.M. contributed to the in vitro 
DNA-Pt(II) studies. I also performed in vitro DNA-Pt(II) studies, including the gel 
analysis of Cu-mediated degradation and MALDI-MS, and was wholly responsible for 
the RNA-Pt(II) work, both in vitro and in vivo. The manuscript was co-authored by 
J.D.W., A.D.M., V.J.D., M.M.H., and myself. This chapter includes work published in 
the Journal of the American Chemical Society (2013, 135, 11680-3, © 2013 American 
Chemical Society). 
 
Picazoplatin, a Novel Azide-Modified Pt(II) Reagent 
 Platinum (II) compounds comprise up to 50-70% of anticancer treatment regimes 
in use today.1 Unlike other classes of common therapeutics such as antibiotics, however, 
a molecular-level understanding of the specific targets of Pt(II) drugs is lacking.2 Pt(II) 
drugs preferentially target purine nucleobases, and drug binding to genomic DNA is an 
accepted cause of downstream apoptotic signaling.3 Less than 10% of Pt (in the case of 
cisplatin) accumulates within genomic DNA,4 and questions remain regarding additional 
targets that could impact cytotoxicity and resistance. A facile and sensitive method for 
drug target analysis would greatly aid such investigations.   
 One synthetic-based strategy for target identification involves modifying Pt(II) 
complexes to contain sterically small bioorthogonally reactive handles. Chemical trans-
formations at this handle (such as reaction with a fluorophore) following drug treatment 
would allow for accurate Pt localization in vivo or subsequent purification of cellular 
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targets.2c Post-treatment labeling circumvents problems associated with using compounds 
modified with bulky or charged fluorophores, which may not accurately represent cellular 
processing of the native drug.2d An ideal candidate for post-treatment labeling is the 
azide-alkyne dipolar cycloaddition, the prototypical click reaction.5 Click chemistry has 
been broadly used for localization and functional studies of modified biomolecules, 
including proteins and nucleic acids.6,7 Despite the importance of Pt(II) compounds in 
therapeutics and catalysis, applications of click reactions on Pt(II) complexes have been 
limited.8 Click reactions have been used as a synthetic route to generate libraries of Pt-
based therapeutics8d-f and for fluorescent post-labeling of a monofunctional Pt(II)-
acridine derivative.9 Our goal is to modify small bifunctional Pt(II) reagents such as 
cisplatin and related compounds (Figure 3.1) for post-treatment analysis. 
 Here, we report the synthesis of the novel azide-functionalized Pt(II) complex 1 
and present DNA oligonucleotide binding and subsequent click reactivity with alkyne-
modified fluorophores (Figures 3.2 and 3.3). We extend these studies to show in vitro 
labeling of a structured RNA oligonucleotide (Figure 3.4) and in vivo treatment and 
post-labeling of yeast ribosomal RNA (Figure 3.5). This tandem Pt binding and post-
modification technique enables visualization and quantification of the cellular targets of 
Pt(II) compounds, and may be broadly applicable towards identification of other metal-
ion based drug targets. 
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Figure 3.1. (a) The anticancer drugs cisplatin and picoplatin, with the novel picoplatin 
analogue 1, picazoplatin. (b) Reaction scheme of biomolecule-bound picazoplatin 
clicking to a dansyl fluorophore. 
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 We designed complex 1 with the azide-functionalized 2-picoline ligand, similar to 
the well-known complex picoplatin (Figure 3.1a).10 Since Pt(II) is capable of catalyzing 
hydroamination and other undesirable side reactions with alkynes,11 the azide-
functionalized complex remained the initial focus of this work. In addition, organoazide 
complexes of Pt, where the azide moieties are connected through organic linkers and not 
directly bound to the Pt center, are known compounds.12 Furthermore, an azide-Pt(II) 
click reagent allows for the future use of nonlinear, ring-strained alkynes and thus 
copper-free click chemistry.13 The steric hindrance provided by the 2-methyl group of 
picoplatin and its derivatives slows the kinetics of substitution reactions on Pt and is an 
important effector of therapeutic activity.10,14 The presence of the 2-methyl substituent 
also prevents the formation of dipicoline adducts and generally yields cleaner syntheses 
compared to other asymmetrically substituted cisplatin derivatives.15 Complex 1 was 
synthesized and fully characterized by 1H and 195Pt NMR, IR, and HRMS (Materials 
and Methods, Figures B.1-B.6, Appendix B). 
 
Picazoplatin-DNA Interactions In Vitro 
Cisplatin, picoplatin, and similar Pt compounds bind readily to 5’-GG-3’-
containing short DNA oligonucleotides and hairpin structures.3a,c,16 Binding of 1 to 
double-stranded DNA and click labeling were analyzed by dPAGE (Figure 3.2). 
Resolution between the denatured strands is clearly observed, and reaction with two-fold 
excess 1 (4 h, 37 °C) results in a new band corresponding to Pt-bound T6GGT5 (Figure 
3.1b, left and center lanes) in yields similar to those observed with the parent compound 
picoplatin (not shown). Reaction of the Pt-bound oligonucleotide with an alkyne 
fluorophore (dansyl propargylamine)17 in the presence of CuI (4 h, 50 °C) results in 
fluorescent labeling of the Pt-bound species (Figure 3.2b, right lane). Observation of the 
expected click product with a single-stranded T6GGT5 construct was confirmed by 
MALDI mass spectrometry (Figure 3.2c).18 The observed Pt-bound species (Figure 3.2c, 
black) shifts to a higher m/z as predicted from cycloaddition of the dansyl fluorophore 
(Figure 3.2c, blue). The click reaction efficiency appears to be high, as the Pt-bound 
peak disappears completely in the clicked (blue) spectrum.  
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 Additional work examining nonspecific interactions between the dansyl alkyne 
fluorophore and the terminal azide of the Pt-bound DNA scaffold was performed with a 
pyrimidine rich DNA hairpin (Figure 3.3a).16 This sequence was selected to minimize 
potential Pt interstrand crosslink formation between hairpins (as was occasionally 
observed for single-stranded T6GGT5, data not shown). A Pt-bound species is not 
resolved under these gel conditions, but fluorescence detection of the subsequent click 
reaction clearly identifies a platinated species. No nonspecific fluorescent labeling is 
observed under Cu-free conditions (Figure 3.3, lane 1) following the reaction of the 
hairpin with two-fold excess 1 (18 h, 37 °C). Proficient fluorescent labeling of the 1-
bound GG DNA hairpin is observed with either CuI-catalyzed (Figure 3.3, lanes 2-3) or 
Figure 3.2. (a) DNA duplex with picazoplatin (1) bound and labeled with dansyl alkyne 
fluorophore. (b) dPAGE analysis showing the denatured complementary strands (left) 
and higher molecular weight Pt-bound species (center). Click reaction with the 
fluorophore results in fluorescence of the Pt-DNA band under UV light (right). (c) 
MALDI mass spectra of Pt-DNA (black) and Pt-DNA-click product (blue) showing the 
change in mass upon binding 1 and reacting with the fluorophore. Expected m/z of 
4301.7 and 4590.8 compared to the observed 4300.03 and 4587.3, respectively. 
Conditions are outlined in Appendix B. 
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CuSO4-catalyzed click protocols (Figure 3.3, lanes 4-5) following incubation at 50 °C 
for 1 h. 
Picazoplatin-RNA Interactions In Vitro and In Vivo 
The presence of Pt(II) lesions in cellular RNAs and their potential downstream 
consequences have become an increasingly important consideration given the many 
regulatory roles of RNA in essential cell processes.19 Recent studies in our laboratory 
have demonstrated that in S. cerevisiae, cisplatin-derived Pt species accumulate to a 
significantly greater extent in RNA versus DNA, with ribosomal RNA acting as a de 
facto cellular Pt sponge.19a In context of E. coli20 and S. cerevisiae19a ribosomal RNA, 
specific Pt binding sites have been identified within the small ribosomal subunit. Pt 
adducts are also observed in the sarcin-ricin loop (SRL), a universally conserved 
exogenous loop essential for elongation factor binding and GTP-dependent translocation 
(unpublished data).21 To establish potential for using Pt-click reagents on cellular RNA, 
we investigated the interaction and click reactivity of 1 on a model SRL RNA construct 
(Figure 3.4). 
 The sensitivity of unmodified (i.e., 2’-OH) RNA species towards degradation by 
Cu-mediated chemistry has previously limited studies of click reactions with RNA 
sequences like the SRL in the absence of protective ligands such as TBTA or under O2-
free conditions.22 We have independently observed significant degradation of our SRL 
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Figure 3.3. (a) DNA hairpin with 1 bound and labeled with the alkyne fluorophore. (b) 
dPAGE analysis showing fluorescent labeling of DNA hairpin by Cu-catalyzed click 
chemistry. Lane 1 contains nonplatinated DNA hairpin and shows no nonspecific DNA-
fluorophore interaction. Lanes 2-5 contain platinated DNA under varying click condition 
sets (Appendix B), all of which show successful DNA-fluorophore labeling. 
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RNA construct under various Cu-catalyzed click conditions (not shown). Recent work 
has demonstrated that trace amounts of acetonitrile stabilize free Cu(I) in aqueous 
solution while still facilitating efficient cycloaddition catalysis.22 Here, we demonstrate 
substantial click product formation from picazoplatin-bound RNA in the presence of 
0.6% v/v acetonitrile (Figure 3.4 and Figure B.7, Appendix B). Lanes 1-3 of Figure 3.4 
show that the SRL RNA is stable in up to 0.8 molar equivalents of Cu(I). In lanes 4-7, a 
supershift demonstrates Pt-adduct formation following RNA treatment with four-fold 
excess 1 (18 h, 37 °C). Notably, lanes 6 and 7 demonstrate efficient Cu(I)-catalyzed click 
labeling to dansyl alkyne fluorophore (1 h, 50 °C). Thus, post-treatment labeling by click 
chemistry is also successful for the analysis of RNA-Pt adducts.
To assess the feasibility of identifying cellular picazoplatin-bound species, we 
extracted and labeled ribosomal RNA from 1-treated S. cerevisiae with Alexa Fluor 488 
DIBO alkyne (Figure 3.5). Lane 1 contains a 200 nucleotide RNA ladder. Lanes 2-4 
contain 5.8S ribosomal RNA treated with an excess of alkyne fluorophore (18 h, 37°C). 
Lane 2 indicates the absence of nonspecific labeling. Lanes 3 and 4 clearly demonstrate 
picazoplatin accumulation on 5.8S rRNA in vivo and successful alkyne fluorophore 
labeling to an intact azide. These studies show the potential for in-gel quantification of all 
Figure 3.4. Fluorescent labeling of Pt-bound RNA SRL hairpin by click chemistry. (a) 
RNA SRL hairpin. Potential Pt binding sites are indicated by starred nucleotides. (b) 
Lanes 1-3: non-platinated RNA is stable in click reaction conditions with 0.4 (triangle) or 
0.8 equivalents (circle) CuI. Lanes 4-7: SRL RNA treated with 4 equivalents 1 shows 
increasing yields of fluorophore labeling following click reactions with 0.4 (lane 6) and 
0.8 (lane 7) equivalents CuI and the dansyl alkyne. Conditions are given in Appendix B. 
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cytoplasmic Pt(II) drug targets and/or fluorescent imaging of Pt trafficking in vivo in 
fixed and permeabilized cells.  
 
Conclusions 
In summary, we report the successful synthesis of picazoplatin, an azide-
containing picoplatin derivative for Pt-bound drug target analysis by click chemistry. 
Picazoplatin ready binds DNA oligonucleotides and undergoes high-yielding click 
reactions with alkyne fluorophores. Moreover, successful fluorophore labeling via 
acetonitrile-assisted click reactions were demonstrated on an RNA mimic of the 
ribosomal sarcin-ricin loop construct, demonstrating viability of this approach in the 
presence of unmodified (i.e. 2’-OH-intact) RNA. Preliminary in vivo applications of this 
technique identified the 5.8S ribosomal RNA as a cellular Pt(II) drug target. 
Future applications of Pt-click reactions could include the isolation, purification, and 
identification of in vivo targets of Pt(II) therapeutics using various alkyne-functionalized 
scaffolds. Reversal of Pt covalent linkages could be achieved by saturation with 
thiourea,18a releasing Pt-bound constituents for analysis via high-throughput sequencing, 
proteomics, or other analytical methods.2c The ability of Pt(II) compounds to crosslink 
Figure 3.5. Fluorescent labeling of 1-treated S. cerevisiae ribosomal RNA by click 
chemistry. Lane 1 contains a 200 nucleotide RNA ladder. Lanes 2-4 contain 5.8S 
ribosomal RNA (approx. 160 nucleotides) extracted from S. cerevisiae treated with 0, 
250, or 500 µM picazoplatin and clicked to an excess of Alexa Fluor 488 DIBO alkyne 
(18 h, 37 °C). Proficient fluorescent labeling of the 5.8S rRNA is observed in vivo. 
Conditions are given in Appendix B. 
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RNA and RNA-protein complexes23 suggests additional applications in RNA and 
ribonucleoproteins structure-function analyses. Such efforts towards using Pt-mediated 
click chemistry to isolate and quantify Pt-bound species are currently underway in our 
laboratory. 
 
Bridge to Chapter IV 
 Chapter III decribes a novel technology for identification, characterization, or 
purification of post-labeled platinum-bound species using click chemistry. This work has 
described picazoplatin (an azide-modified derivative of picoplatin) binding throughout 
RNA and DNA oligomers in vitro, confirmed by in-gel fluorescent detection and 
MALDI-MS analysis. Importantly, this is the first example of fluorescent post-labeling of 
platinum bound 5.8S rRNA as observed in RNA from picazoplatin-treated cells. Chapter 
V uses this technique to characterize platinum accumulation within rRNA and tRNA in 
picazo- and cisplatin treated S. cerevisiae.  
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CHAPTER IV 
 
CLICK FLUORESCENT LABELING AND ENZYMATIC MAPPING OF 
PLATINUM (II) COVALENT DRUG MODIFICATIONS IN SACCHAROMYCES 
CEREVISIAE RIBOSOMAL RNA 
 
 This chapter contains ideas co-developed by Dr. Victoria J. DeRose and myself. I 
wrote the entirety of the manuscript, and received significant editorial feedback from 
V.J.D. Picazoplatin was synthesized by Jonathan D. White.  
 
Introduction 
 Cis-diamminedichloroplatinum (II), or cisplatin, is a widely prescribed anticancer 
compound and currently one of only three Pt(II) complexes that are FDA approved for 
cancer treatment. In tumors, nuclear DNA damage from Pt(II) initiates apoptotic 
signaling, but this activity is not necessary for cytotoxicity. The accumulation and 
consequence of Pt(II) lesions on non-DNA targets, such as RNA, are largely unexplored. 
We previously reported the synthesis of an azide-functionalized Pt(II) species, 
picazoplatin, for post-treatment click labeling and isolation of Pt targets in vivo (White et 
al., JACS 2013). Here, we report in-gel fluorescent detection of Pt-bound ribosomal RNA 
and transfer RNA extracted from picazoplatin-treated S. cerevisiae and labeled using 
copper-free click chemistry. These data provide the first evidence that cellular tRNA is a 
platinum substrate and demonstrate a convenient click chemistry methodology that can 
be applied to identify other metal or covalent modification-based drug targets. We 
assessed Pt(II) binding within regions of ribosomal RNA where damage is linked to 
significant downstream consequences. Pt(II) lesions were mapped to nucleotide 
resolution on the sarcin-ricin loop (SRL) Helix 95 from ribosomal RNA extracted from 
cisplatin-treated S. cerevisiae as well as on a model SRL oligomer. Binding occurred on 
the nucleotide substrates of ribosome-inactivating proteins, as well as on the bulged-G 
motif critical for elongation factor recognition of the loop. At therapeutically relevant 
concentrations, Pt(II) also binds robustly within conserved cation-binding pockets in 
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Domains V and VI rRNA at the peptidyl transferase center. Taken together, these results 
suggest a ribotoxic mechanism for cisplatin cytotoxicity.  
 
Pt(II) Lesions within Cellular RNAs  
 Cisplatin is the preeminent compound in a limited class of universally prescribed 
platinum (II) anticancer therapeutics. These small molecules form exchange-inert 
crosslinks with a variety of biomolecular targets, particularly across stacked guanine 
bases of nucleic acids. Formation of irreparable crosslinks on DNA induces programmed 
cell death in tumors (1). However, as less than 10% of intracellular cisplatin accumulates 
on DNA, cytotoxicity and alternative cell death pathways caused by additional platinum 
modifications is a major interest (2). We are specifically interested in assessing platinum 
modifications in cellular RNA, which may be a significant molecular decoy and 
secondary Pt(II) target. In Saccharomyces cerevisiae, we have shown that cisplatin-RNA 
adducts are more prevalent than in DNA (3). Cisplatin binding has been observed in vitro 
within rRNA (3, 4), tRNA (5), siRNA (6–8), and miRNA (9). Platinum lesions on RNA 
are not well-tolerated; disruptions to RNA-based processes are observed where structure 
and function are tightly coupled, such as ribosomal RNA synthesis, splicing, and 
translation (10–13). Moreover, there is developing recognition that RNA damage may 
contribute to cellular apoptotic signaling (14, 15). There is a clear need to characterize the 
molecular RNA targets of platinum, especially those which may initiate cytoplasmic 
cytotoxicity.  
Here, we show in-gel visualization of post-treatment labeled cytoplasmic cisplatin 
targets and characterize, to nucleotide resolution, Pt(II) binding within the sarcin ricin 
loop and peptidyl transferase center of the ribosomal large subunit. These studies show 
the potential for ribotoxic response to chemotherapies, as well as structural insight into 
the ability of a small divalent metal to form crosslinks in unique RNA structures. 
 
Click Fluorescent Tagging and Identification of Pt-bound RNA 
 We recently developed a method to detect platinum-modified targets through 
bioorthogonal ligation of Pt-bound species to alkyne-containing fluorescent probes 
(Figure 4.1) (16). Post-treatment modification allows the Pt compound to bind without 
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potential interference from attached labels, such as fluorescent dyes, and has also been 
used recently in studies of acridine-modified Pt compounds (17). Here, we use 
picazoplatin, an azide-functionalized click-capable derivative of picoplatin, to obtain 
dose-dependent fluorescent post-labeling of S. cerevisiae ribosomal RNA and transfer 
RNA (Figure 4.2). In-gel fluorescence scanning reveals significant fluorescent labeling 
of the 25S, 18S, 5.8S, and 5S ribosomal RNA bands. The broad distribution of 
fluorescent labeling between all ribosomal subunits demonstrates the environmental 
accessibility of rRNA towards covalent Pt modifications in vivo. This approach allows a 
rough quantification of Pt lesions per RNA based on signal intensity, with an estimated 
detection limit of ~1 Pt per 10,000 nt (see Appendix C). Using this calculation, we 
estimate ~0.4 platinum molecules per ribosome following treatment with 250 µM 
picazoplatin (Table C.1). This agrees well with previous work quantifying cisplatin 
accumulation as 1-2 per ribosome following 6 h of 100 or 200 µM cisplatin treatment (3), 
especially since picoplatin, the picazoplatin parent compound, has slower substitution 
kinetics (18, 19). Based on the signal intensity in the smaller 70—100 nt RNAs, it 
a) 
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Figure 4.1. (a) The platinum (II) therapeutics cisplatin, oxaliplatin, picoplatin, and click-
capable picazoplatin. (b) Copper- free fluorescent labeling of a picazoplatin-bound 
nucleic acid with Alexa Fluor 488 DIBO alkyne.   
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appears that Pt is accumulating to a much greater degree, on the order of ~0.8 Pt per 
tRNA (Table C.1).  
To our knowledge, this is the first indication of Pt(II) accumulation in 
cytoplasmic tRNA. The functional consequences of Pt-tRNA adducts are unknown but 
are predicted to perturb their regulatory function. For instance, damage to tRNAs directly 
impacts RNA metabolism, may be a cellular signal of oxidative stress, and is indirectly 
linked to enhanced apoptotic signaling due to an increase in free cytochrome c (15, 20, 
21). The observation of the accumulation of Pt(II) species on tRNA is especially 
intriguing given that damaged tRNAs, once sensed, are expected to have reduced half-
lives, sometimes as short as minutes (22). However, given that tRNAs are already highly 
modified RNA species that fold into complex and diverse tertiary structures, their 
function may be more tolerant to Pt lesions. For example, certain nucleotide 
modifications are suggested to exert stabilizing effects by restricting conformational 
flexibility on the angstrom scale (23), thus reducing the propensity for enzymatic or base-
25S rRNA 
18S rRNA 
5.8S rRNA 
5S rRNA 
tRNA 
Methylene blue  
RNA stain 
Alexa Fluor 488 DIBO  
alkyne fluorescence 
0          250       500              0        250        500 
 
Picazoplatin (µM) Picazoplatin (µM) 
Figure 4.2. In-gel fluorescent analysis of post-labeled Pt-bound rRNA and tRNA purified 
from picazoplatin-treated S. cerevisiae. Cells were treated with 0, 250, or 500 µM for 6 h. 
Harvested RNAs (~5 µg) were reacted with an excess of Alexa Fluor 488 DIBO alkyne (18 
h, 37° C), RNeasy column purified, and analyzed via 15% dPAGE. Dose-dependent 
labeling of tRNA and 25S, 18S, 5.8S, and 5S rRNA is observed. Fluorescence (panel, R) 
colored for clarity using Adobe Photoshop. Conditions provided in Appendix C. 
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catalyzed degradation. As an additional factor, cisplatin lesions prevent exo- and 
endonuclease digestion of a number of RNA species (24). An accumulation of Pt-bound 
tRNA could result in nuclear mislocalization, as is seen in unspliced or modified tRNAs 
(25). Furthermore, elevated levels of tRNAs are implicated in some disease states (26, 
27).  
 
Enzymatic Mapping of Pt(II) Adducts in S. cerevisiae Ribosomal RNA  
 It is of interest to characterize Pt(II) modifications within RNAs that are 
functionally susceptible to substitutions, metal ion-mediated cleavage, or structural 
modifications. In rRNA, these regions are clustered in domains V and VI, within in the 
functional core of the ribosome (28–31). Certain modifications in these domains are 
capable of initiating a ribotoxic stress response in actively translating ribosomes, which 
we hypothesize may contribute to cisplatin cytotoxicity (32, 33). One particularly 
sensitive rRNA motif is the sarcin ricin loop (SRL), a universally conserved and purine-
rich 12 nt sequence located adjacent to the peptidyl transferase center (PTC). The SRL (S. 
cerevisiae helix 95) folds in a robust and energetically stable distorted hairpin containing 
several flexible non-Watson Crick base pairs and unique motifs, including a GAGA 
tetraloop, a bulged G-motif, an S-turn, and a terminal A-form duplex (34). It scaffolds 
several critical protein-RNA interactions within the ribosome and is the target of 
ribosome inactivating proteins (RIPs) such as α-sarcin and ricin, proteins that 
catalytically modify the capping loop of the SRL, inhibiting the elongation step of 
translation and inducing apoptosis (35). Point mutations and structural perturbations 
within the SRL, such as those which may be induced by platinum crosslinking, are lethal 
(35, 36). Additionally, the SRL is proposed to host several cation-binding pockets, which 
could facilitate platinum coordination (37). Therefore, given the structural properties of 
this motif and potential for its modification to cause significant downstream 
consequences, we have carefully examined cisplatin accumulation in the SRL of RNA 
isolated from S. cerevisiae following cisplatin treatment.  
 Primer extension analysis, in which a reverse transcriptase stalls 3’ to a platinum 
adduct, was used to identify platinum binding pockets in the region of the SRL (helices 
95 and 96, Figure 4.3 and Figure C.1) and adjacent solvent accessible and mobile 
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helices in the PTC (helices 90 and 93, Figure C.3). Such crosslinks are expected to 
primarily occur between the N7 positions of purines that are in close proximity. 
Accompanying a quantitative ICP-MS analysis of Pt on S. cerevisiae rRNA, we 
previously performed a limited identification of Pt sites within helix 18 in the small 
ribosomal subunit (3) and compared them with a prior report from E. coli (4). Differences 
in rRNA sequence led to a shift in preferred Pt binding sites in the two organisms, 
demonstrating in vivo sequence selectivity. Within the S. cerevisiae SRL, extension data 
using two different primers provides clear evidence for concentration-dependent platinum 
adducts (Figures 4.3 and C.2). A strong stop at U3037 indicates a 5’-ApG-3’ adduct 
between G3036:A3035. In DNA helices, this sequence is known to be kinetically 
Figure 4.3. Primer extension analysis of the sarcin-ricin loop (SRL) region in ribosomal 
RNA extracted from S. cerevisiae treated with 0—200 µM cisplatin. Dideoxy sequencing 
ladder labeled by A, U, C, and G. Cisplatin-induced stop sites are denoted by asterisks (*) 
and represent nucleotides 3’ to a stable platinum adduct. Colored asterisk denotes 
primary stop site in terminal SRL region (at G3028) according to line plot analysis. 
Predicted platinum crosslinks between adjacent purines based on experimental results are 
colored on the S. cerevisiae secondary structure map. The 12 nt universally conserved 
RNA sequence is in bold. M. musculus and E. coli sequences provided for comparison. 
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preferred over the opposite 5’-GpA-3’ (38). A second clear stop site occurs at U3023, 
indicating Pt(II) binding at the bulged-G motif (G3022) critical for loop recognition by 
elongation factor 2 (EF-G, E. coli) (39). Depending on the flexibility of this non-Watson-
Crick basepaired nucleotide, this could represent a monofunctional Pt(II) adduct on 
G3022 or a 5’-ApG-3’ adduct between A3021:G3022. Disruption of RNA-protein 
interactions at G3022 is directly linked to translation inhibition and ribotoxic response 
signaling (39, 40). The third clear stop within the sarcin ricin loop is at the 5’ distal end 
of the helix. Experiments with the ‘upstream’ SRL primer experiments show significant 
stops at A3017 (Figure C.2). As this is a relatively purine-rich stretch of the stem, we 
conclude that platinum could form a 5’-GpA-3’ diadduct between G3015:A3016.  
 In primer extension of the highly conserved and purine-rich terminal SRL loop, 
multiple stop sites arise in RNA isolated from cells treated with increasing cisplatin 
concentrations.  The multiple but nonspecific stop sites in the region between G3033 and 
G3026 indicate that platinum binding in or near to this loop causes rigid secondary 
structures that are nonpermissive to RT extension. From the in vivo data it is difficult to 
ascertain specific platinum adducts; for comparison, we extended these studies to 
investigate in vitro platinum binding within a SRL oligomer (vide infra). However, line 
plot analyses for both primers suggest a primary stop site within this region at A3029 
(Figure C.2) or G3028 (Figure 4.3), suggesting formation of a Pt(II) adduct between 
G3028:A3027 or a monofunctional adduct at A3027. A3027 is moderately reactive in in 
vivo SHAPE analyses, indicating some degree of conformational flexibility (41). Ricin 
specifically depurinates A3027, while α-sarcin cleaves the phosphodiester backbone 
between A3027 and G3028, and both types of damage culminate in apoptosis (33). We 
hypothesize that the observed Pt(II) lesions may elicit a similar ribotoxic response.  
 Throughout helix 96, the helix directly adjacent to the SRL, platinum 
accumulation is observed on adjacent, stacked purines at therapeutically relevant 
treatment conditions as low as 100 µM cisplatin, which we have previously correlated 
with a cytoplasmic concentration of 47 µM (3). In regions of stable duplex RNA and 
longer hairpins, we generally observe stable 3’-GG-5’ Pt (II) intrastrand adducts. In 
regions which may exhibit flexibility, such as the H95:H96:H97 three-helix junction (42), 
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primer extension is terminated on the first guanine of a 3’-GG-5’ pair (G3044:G3045), 
suggesting a monofunctional adduct or long-range RNA crosslink (Figures 4.3 and C.1). 
 One facet of cisplatin’s effect on RNA-dependent cellular processes is the 
inhibition of translation elongation (43). We therefore assessed platinum binding within 
helix 93, one of the mobile stalks of the peptidyl transferase center (Figure C.3). This 
structure is adjacent to the aa-tRNA accommodation corridor and hosts A2971 in its stem. 
This particular adenine is the most conformationally flexible residue in the PTC and was 
found to be strongly reactive to SHAPE 2’-OH modification in E. coli and S. cerevisiae 
in the absence of tRNA in purified ribosomes (41). Moreover, mutations at A2971 
strongly interfere with peptide release (29). From our primer mapping data, a strong stop 
site at G2973 suggests that A2971 is also highly reactive to platinum crosslinking, 
forming a crosslink with G2972 (Figure C.3). This data suggests the Pt(II) adduct 
occurred in an A-site tRNA unbound (i.e. Pt (II) accessible) state, providing a mechanism 
to inhibit further translation. Intriguingly, although the broad reactivity of platinum 
towards adjacent purines is well established, cisplatin binding in this region is remarkably 
specific; several purines in helix 93 (G2956, A2957, G2965, A2966, G2967, and A2968) 
are unreactive towards Pt (II). Figure 4.4 depicts H93 in the context of a tRNAMet-bound 
ribosome. In this structure, the purine nucleotides G2966 and A2967 in the terminal loop 
of H93 (orange) are organized around a ~2.8Å hydrogen bond to the 2’OH of the G2964 
ribose sugar (aqua). This interaction may preclude stable Pt(II) diadduct formation 
between G2966:A2967, and explain a general mechanism for protection at this loop. 
However, A2971 (yellow) is clearly flipped out from the helix and in a position ready to 
bind Pt(II). This may account for our observation of strong targeting to A2971, while the 
H93 terminal loop appears shielded (Figure C.3).  
 In this investigation of Pt(II) adduct formation within the PTC, we also uncovered 
several Pt(II) binding sites in helix 90, corresponding to 1,2-intrastrand GpG adducts. 
These results are somewhat obscured by the prevalence of RNA modifications within 
these sequences (Figure S3). However, they clearly depict the ability of Pt(II) to target 
accessible purine bases within a complex RNA structure. The summary of these analyses 
is presented in the rRNA secondary structure map in Figure 4.5.  
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Figure 4.4. Model depicting H93 (aqua) in the context of a tRNAMet-bound ribosome 
(tRNA: red; rRNA: gray; protein: light purple). G2966 and A2967 in the terminal loop of 
H93 (orange) are organized around a ~2.8Å hydrogen bond to the 2’OH of the G2964 
ribose sugar (aqua). A2971 (yellow) is clearly flipped out from the helix and in a position 
accessible for Pt(II). Figure generated in PyMOL using PDB files 4BYT, 4BYS, 4BYP, 
4BYR, 4BYQ, 4BYO, 4BYN, AND 4BYL. 
Figure 4.5. Model of platinum binding within helices 90, 93, 95, and 96 of the S. cerevisiae 
large ribosomal subunit RNA. Crystal structure of rRNA (gray left) is shown with probed 
regions highlighted in color and expanded to show platinum dinucleotide crosslinks in 
orange (middle). Crosslinks agree well with proposed solvent accessibility and nucleotide 
position according to the crystal structure. Pt (II) sequence specificity is summarized on the 
left, with sites of moderate (w) and high (ww) SHAPE reactivity overlaid (41). The 2 D 
structure map of yeast rRNAs was obtained from the Comparative RNA Website (47). 
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Enzymatic Mapping of Pt(II) Adducts in a Model SRL RNA  
 To compare accessibility to Pt in vivo with an in vitro model, platinum adducts 
within a 27 nt model SRL oligomer were probed using primer extension analysis. From 
NMR structural data and molecular simulations, this sequence is well-understood to fold 
into a stable structure in vitro, allowing our 27 nt oligomer to accurately model the SRL 
in the context of the 25S rRNA (34, 44). We have assessed aquated (“activated”) cisplatin 
binding within the SRL from 0—2 equivalents (Figure 4.6). We observe dose-dependent 
platinum stop sites occurring at U3036, A3031, G3030, and A3026 (S. cerevisiae 
numbering). The platinum adducts predicted by these stop sites are highlighted in color in 
the S. cerevisiae secondary structure map. They include a canonical 3’-GG-5’ adduct 
(G3031:G3030), two putative 3’-GA-5’ intrastrand crosslinks (G3036:A3035; 
G3030:A3029), and a signal at an isolated guanine which could represent a 
monofunctional adduct or a crosslink bridging the terminal GAGA tetraloop (G3026). As 
described earlier, there is a strong causal link between damage at this position and 
downstream apoptotic signaling. It is important to note that under these conditions, it is 
likely that each RNA is bound by multiple Pt(II) atoms. Due to the 3’ bias of this 
technique, it is difficult to define where 1,2-intrastrand Pt(II) lesions form on the 5’ distal 
Figure 4.6. Primer extension analysis of a folded model S. cerevisiae sarcin ricin loop 
RNA following treatment with 0—2 equivalents of aquated cisplatin or 0—10 
equivalents of non-aquated oxaliplatin (20 h, 37° C). Cisplatin-induced dose-dependent 
stop sites are denoted by asterisks. Oxaliplatin-induced stop sites mimic those of 
cisplatin, and are shown for comparison.  Mapping results are summarized in the 
secondary structure diagram using the same notation as in Figure 4.3. 
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region of the duplex.   	  
Cisplatin accumulation within the model SRL was compared to the RT stalling pattern 
following SRL treatment with non-activated oxaliplatin (Figure 4.6). The equilibria, 
mechanism, and rates of aquation and binding differ between cisplatin and oxaliplatin 
and depend strongly on pH and ionic environment (45). For oxaliplatin, dissociation of 
the oxalato ligand is reported to occur with a half-life of 92 min at 37 °C (46). In our 
studies, 10 equivalents of non-activated oxaliplatin are required to observe RNA-Pt(II) 
adducts, compared with just 0.5 to 1 equivalents of activated cisplatin. Remarkably, 
despite these differences, their kinetically preferred binding sites are identical within the 
SRL. Conservation of Pt (II) binding within the SRL may demonstrate a ubiquitous 
mechanism for translation inhibition. This differs from  
 Finally, we report that the pattern of platinum accumulation differs slightly 
between the sarcin ricin loop in vitro model versus the in vivo and presumably intact 
ribosome (Figure 4.7). Platinum crosslinking throughout the helix stem (at 
A3035:G3036) is completely conserved, but the preference of platinum slightly shifts 
within the GAGA tetraloop in vivo. We observe Pt(II) accumulation within A3027 and 
G3028 by two different primer extension assays. However, neither nucleotide is Pt(II)-
bound in our in vitro model (Figure 4.7). This may be explained in part by anti/syn base 
Figure 4.7. Model comparing differences in Pt(II) binding preferences within the SRL in 
vitro and in vivo. Predicted platinum adducts are denoted by “Pt”. Pt(II) binding is 
conserved throughout the SRL with the exception of the GAGA tetraloop. In vivo, strong 
Pt(II) targeting is observed to A3027 and G3028 (Pt, orange). This targeting is not 
conserved in vitro. Figure generated in PyMOL using PDB files 3O5H and 3O50. 
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flipping of the terminal adenine as predicted by molecular simulations (34). According to 
Sponer et al., although the SRL is highly rigid when compared to other RNA motifs, the 
tetraloop is dynamic. Given that several protein interactions occur at the tetraloop that 
may induce unfolding or stabilization, we predict a concurrent change in platinum 
accessibility and binding. The change in the binding pattern could also reflect RNA-
protein crosslinks, which are absent in our in vitro model.  
 
Conclusion 
 To date, we lack a comprehensive understanding of the biological cytoplasmic 
substrates of Pt(II) therapeutics such as cisplatin. We recently developed a method to 
detect platinum-modified drug targets using picazoplatin, an azide-containing picoplatin 
mimetic designed for post-treatment labeling via click chemistry. Here, we demonstrate 
that ribosomal RNA and transfer RNA purified from picazoplatin-treated yeast 
accumulate platinum and are efficiently labeled with Alexa Fluor 488 DIBO alkyne to 
levels detectable by in-gel fluorescence (following 250 µM treatment, ~0.4 Pt per 
ribosome and ~0.8 Pt per tRNA). This is the first evidence that tRNA is an authentic 
platinum substrate. Pt-tRNA damage could severely impact cellular processes such as 
translation and apoptotic signaling. Within ribosomal RNA, we have identified the sarcin 
ricin loop and peptidyl transferase center as high impact cisplatin targets. Using primer 
extension analysis, we have mapped platinum accumulation on the sarcin ricin loop in 
vivo on rRNA extracted from yeast treated with cisplatin as well as in a model 27 nt 
oligomer. This investigation of Pt(II) adducts within Domains V and VI rRNA 
demonstrate a variety of potential ribotoxic roles for platinum, all of which likely 
contribute to the general cytotoxicity of the drug. Using picazoplatin, future avenues of 
research could focus on isolation, enrichment, and sequencing of platinum-bound nucleic 
acids to gain a global perspective on Pt accumulation and RNA access in vivo. We are 
very interested in dissecting the accumulation of cisplatin on its cellular targets with 
temporal resolution, as the types of Pt-RNA interactions we have described could be of 
cytoplasmic or nucleolar origin. Of critical importance is the demonstration that this 
azide modification technique can be broadly utilized to assess the binding preferences of 
other small molecules on cellular RNAs. 
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Bridge to Chapter V 
 In Chapter IV, we report significant in-gel fluorescent detection of Pt-bound 
ribosomal RNA and transfer RNA extracted from picazoplatin-treated S. cerevisiae using 
copper-free click chemistry, and demonstrate the first evidence that cellular tRNA is a 
platinum substrate. Building on this insight, we have identified the sarcin-ricin ribosomal 
RNA loop as an impactful drug target. We have mapped cisplatin accumulation to 
nucleotide resolution on the sarcin-ricin loop (SRL) from ribosomal RNA extracted from 
cisplatin-treated S. cerevisiae as well as on a model SRL oligomer. At therapeutically 
relevant concentrations, Pt(II) binds robustly within conserved cation-binding pockets in 
Domains V and VI rRNA. Taken together, these data suggest a ribotoxic mechanism for 
cisplatin cytotoxicity, and broadly describe a convenient click chemistry methodology 
that can be applied to identify other metal or covalent modification-based drug targets. 
Chapter V summarizes the research described in Chapters I through IV, and provides a 
perspective on the future outlook of platinum therapeutics. 
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CHAPTER V 
 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
 I am very privileged to have spent my graduate career in a highly collaborative 
environment. Many of my co-workers research complementary aspects of cisplatin 
biochemistry, and as such, I have received invaluable input, assistance, and guidance 
from former and present DeRose lab members, including Dr. Erich G. Chapman, Dr. W. 
Luke Ward, Dr. Alethia A. Hostetter, Jonathan D. White, Kory J. I. Plakos, Rachael M. 
Cunningham, and Alan D. Moghaddam. This chapter is a synopsis of the creative ideas 
seeded by Dr. DeRose and developed throughout generations of graduate work, and my 
personal view on the future outlook of platinum (II) therapeutics. 
 
Concluding Remarks 
 This dissertation describes cellular RNA targeting by platinum (II) 
chemotherapeutic drugs. Chapter I summarizes the history, molecular mechanism, and 
current literature on Pt(II) therapeutic targets and anticancer activity. Here, I have 
introduced the concept of Pt(II) sequestration by cellular RNA, and discussed the 
potential for RNA as a drug target. Chapter II recounts our work characterizing the 
distribution of Pt(II) within S. cerevisiae cytoplasmic RNA, with the discovery that 
ribosomal RNA acts as a de facto cellular platinum sponge, forming stable covalent 
adducts following just 1 h of drug exposure. We learned about the sequence specificity 
and reactivity of cisplatin towards complex RNA hairpins in vivo, validating many in 
vitro RNA-Pt(II) studies performed by my predecessors. Interested in extending this work 
to a more high-throughput system, current work is focused on developing a suite of click-
capable platinum(II) reagents for the purpose of post-labeling, isolating, or purifying 
platinum-bound species. Specific routes toward those goals are outlined in Figure 5.1. 
One intriguing possibility  would be the use of alkyne-functionalized biotin to enrich for 
platinum-containing species on streptavidin functionalized beads or surfaces (Figure 5.1, 
top right). Following target capture, the selected biomolecules could be released using 
thiourea reversal of Pt(II) binding, a method developed by Dr. Erich G. Chapman.1 Then, 
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sequences could be subjected to mass spectrometry (proteins, lipids) or high-throughput 
sequencing (nucleic acids) for characterization. Alan D. Moghaddam and Rachael M. 
Cunningham are actively pursuing these types of assays.  
 Chapter III describes our first proof-of-principle studies with picazoplatin, an 
azide-functionalized picoplatin derivative. Here, we have shown a novel method for in-
gel fluorescent detection of Pt-bound DNA and RNA oligomers, as well as labeling of the 
5.8S ribosomal RNA subunit from picazoplatin-treated S. cerevisiae. Currently, Jonathan 
D. White and Alan D. Moghaddam are engaging in the synthesis and application of more 
reactive azide-functionalized complexes, such as 2-ADAP Pt (Figure 5.1). These 
complexes have opened up a number of new avenues for innovative research in the 
DeRose lab. Currently, Rachael M. Cunningham is developing an assay using 2-ADAP 
Pt to monitor platinum accumulation on cellular proteins. Kory J. I. Plakos is using 2-
ADAP Pt as a platinum crosslinking reagent to study the tertiary structure of folded 
ribozymes.  
 In Chapter IV, I recount the first in-gel fluorescent detection of picazoplatin-
bound RNA species within total RNA isolated from drug-treated S. cerevisiae. From 
these data, we report Pt accumulation on the order of ~0.5 Pt per ribosome, and ~0.8 Pt 
per tRNA. This is the first evidence of tRNA as a bona fide cisplatin substrate in vivo, 
which could severely affect translation or apoptotic signaling. Chapter IV also describes 
my methodical investigation of Pt(II) binding within the functional core of the ribosome, 
in an effort to understand how Pt(II) lesions could contribute to the inhibition of 
translation observed in cisplatin-treated cellular extracts. We detect stable Pt-RNA 
modifications throughout several critical RNA motifs, including the sarcin-ricin loop and 
peptidyl transferase center.  These studies demonstrate a variety of potential ribotoxic 
roles for platinum, all of which likely contribute to the general cytotoxicity of the drug. 
Translation is not the only RNA dependent process altered following cisplatin treatment; 
currently, Emily R. Morris is investigating the effects of cisplatin on alternative mRNA 
splicing. Taken together, the work described in this dissertation highlights the 
significance of RNA targeting by cisplatin and disseminates a novel technology (Pt(II) 
click chemistry) which could be broadly applied in the identification of targets of metal-
based drugs.  
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Current Limitations on Use of Pt(II) Drugs and Future Outlook 
 Chapter I summarized the historical progression of platinum antitumor agents 
through the FDA approval process. Cisplatin was approved for use in the U.S. in 1978. 
Since then, 23 complexes have entered clinical trials, with only two gaining approval 
(carboplatin and oxaliplatin).2 No new Pt(II) drug has been promoted to clinical trials 
since 1999.3 This is partially explained by an increase in stringency of FDA regulations; 
however, to date, the major issues of toxicity and resistance are still problematic. High 
doses of Pt(II) agents results in ototoxicity, neurotoxicity, myelosuppression, and acute 
nephrotoxicity, as the body attempts to clear the drug through the kidneys. The side 
effects suffered may require sub-lethal doses, which cause tumor cells to develop 
resistance. Resistance is mediated through reduced uptake and inactivation of the drug 
Figure 5.1. Potential applications for click-capable Pt(II) reagents. (Top left) Click 
pulldown of Pt-bound RNA for high-throughput sequencing. (Top right) Click to biotin-
alkyne for facile detection or pulldown of labeled species. (Bottom left) Fluorescent 
tracking of cellular Pt(II) species in tissue culture. (Bottom right) Use of a strained alkyne 
fluorophore for Cu-free labeling of RNA in vitro. 
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via sequestration to intracellular thiols.3 This has led research to shift towards 
development of DNA-targeting Pt(II) ligands,4 photoactivatable Pt(IV) prodrugs,5 and 
tumor-specific lipophilic delivery systems.6 These advances may alleviate issues 
associated with side effects in non-tumorigenic cells, allowing treatment with higher 
dosages. However, they do not fully address issues of intracellular resistance. If a 
comprehensive study of Pt(II) cellular targets was performed using reagents such as 
picazoplatin and 2-ADAP Pt, it would allow precise quantification of the distribution and 
localization of platinum drugs. Using this technique, we are the first to demonstrate that 
cellular tRNA is a major target of platinum binding in vivo in treated S. cerevisiae. 
Discoveries like this would directly enhance development of novel or non-classical 
platinum-based anticancer therapeutics. Moreover, there is a clear need to understand the 
effects of targets such as rRNA and tRNA, especially given the recent expansion of 
knowledge regarding RNA damage sensing, repair, and regulation. New chemical 
strategies like our click-capable Pt(II) species will be invaluable for the advancement of 
platinum therapeutics.    
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APPENDIX A 
 
SUPPORTING INFORMATION FOR CHAPTER II: RNA-PT(II) ADDUCTS 
FOLLOWING CISPLATIN TREATMENT OF SACCHAROMYCES CEREVISIAE 
 
Materials and Methods 
Cell cultures and treatments: S. cerevisiae strains BY4741 (MATa; his3D1; leu2D0; 
met15D0; ura3D0), yca1D (BY4741 yca1::kanMX4) and aif1D (BY4741 aif1::kanMX4) 
were gifts from the Stevens laboratory at the University of Oregon. Liquid cultures were 
grown on Synthetic Complete medium (SC) consisting of 0.67% yeast nitrogen base and 
2% glucose supplemented with amino acids and nucleotide bases maintained in the dark 
at 30 °C with shaking at 200 rpm. Plated cells were grown on YEPD agar plates (1% 
yeast extract, 2% peptone, 2% glucose, and 2% agar). A 5 mM cisplatin (Sigma Aldrich) 
stock in 100 mM NaCl (stored in the dark for no more than a week) was used for all 
cisplatin treatments. Yeast cultures were pregrown to an OD600 of 5 then inoculated into 
30 °C cisplatin-containing media to an OD600 of 0.075.  
 
Culture growth, cell survival, and cell size: Culture growth was measured by 
absorbance at 600 nm (1 AU600 = 2.0 × 107 cells/mL). Cell viability was measured by 
plating serial dilutions of treated and untreated yeast, at given growth times, onto drug-
free YEPD agar plates (~250 cells/plate) and counting colonies after 3 d at 30 °C. The 
number of colony-forming units (cfu) was determined by dividing the cfu counts of 
treated cultures by those of untreated cultures (assumed to be 100%). Yeast cell radii 
were measured from differential interference contrast images obtained on a Carl Zeiss 
Axioplan 2 fluorescence microscope using a 100× objective and AxioVision software 
(Carl Zeiss, Thornwood, NY) and volumes were calculated by treating the yeast as 
spheres.  
 
Nucleic acid extraction and purification: For measurements of Pt in total RNA ~1.2 × 
108 cisplatin treated yeast cells were pelleted and RNA was extracted using the 
MasterPure RNA Purification Kit (Epicentre) according to manufacturer’s specifications. 
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For both mRNA and rRNA samples total RNA was extracted from cisplatin treated cells 
according to the method of Motorin et al. (1). Poly(A)-mRNA was isolated using 
GenElute mRNA Miniprep Kit (Sigma), doing the binding and wash steps twice to ensure 
maximum mRNA purity. Ribosomal RNA was isolated from total RNA using 8% 
dPAGE. The 25S and 18S bands were visualized by brief staining with methylene blue, 
cut out and eluted with an Elutrap Electroelution System (Whatman), then desalted (3k 
Microsep Centrifugal Devices, Pall). DNA samples were purified as in Rose et al. 
including the optional RNase A treatment (2). Because Pt adducts on RNA are known to 
inhibit RNase activity (2) DNA was extracted at 12 h, a time at which there is 4–5 fold 
lower RNA content in yeast cell (3), in order to ensure sample purity. All pellets were 
collected at 4 °C and washed 3 times with deionized H2O before further processing.  
 
Measurement of Pt content: Isolated RNA and DNA samples were desalted on in-house 
prepared G-25 sephadex spin columns (BioRad) and quantified by absorbance at 260 nm. 
Whole-cell and most nucleic acid samples were digested in 70% nitric acid (trace select, 
Fluka) for 2 hours at 65oC then diluted to 2% (v/v) nitric acid with milli-Q H2O. Pt 
content was determined by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
using a Thermo VG PQExcell quadrupole ICP-MS equipped with a Gilson 222 
autosampler at the W. M. Keck Collaboratory for Plasma Spectrometry (Oregon State 
University, Corvallis, Oregon). The instrument was calibrated for 194Pt, 195Pt and 196Pt by 
developing standard curves from a Pt standard (High Purity Standards). All 
measurements were done in triplicate using 115In as an internal standard.  
 
Tests for apoptotic markers: Terminal deoxynucleotidyl transferase-mediated dUTP 
nick end labeling (TUNEL) was performed according to the method of Madeo et. al. (59) 
with the following modifications: cell walls were digested with 2.5 U zymolyase 100T 
(US biological) for 30 min at 30 °C in 1 mL sorbitol buffer (1.2 M sorbitiol, 0.5 mM 
MgCl2, 35 mM phosphate buffer pH 6.8), the permiabilization was carried out for 1 min, 
and the in situ cell death detection kit, fluorescein (Roche), was used with a 30 min 
incubation (full protocol Supplementary pS4). Positive control samples were incubated 
with 0.2, 1, and 5 U DNase I (Fermentas) for 1 h at 37 °C in the manufacturer’s rxn 
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buffer. Images were acquired on a Carl Zeiss Axioplan 2 fluorescence microscope as 
described above. DAPI staining was performed by pelleting 1.0 × 107 yeast cells, 
washing 3x with PBS, fixing in 70% (v/v) EtOH for 30 min, washing with PBS, and then 
incubating with 0.5 mg/mL DAPI for 20 min (in the dark). The samples were then 
washed 3x with PBS and visualized immediately. 
 
Full TUNEL protocol: Yeast cells (3.0 × 107) were pelleted, washed 3x with PBS, fixed 
with 3.7% (v/v) formaldehyde for 2 h at 24 °C, and then digested with 2.5 U zymolyase 
100T (US biological) for 30 min at 30 °C in 1 mL sorbitol buffer (1.2 M sorbitiol, 0.5 
mM MgCl2, 35 mM phosphate buffer pH 6.8). A portion of the sample was applied to a 
polylysine-coated slide and let dry for 1 h at 37 °C. The slides were incubated with 
freshly prepared permiabilization solution (0.1% Triton X-100, 0.1 sodium citrate) for 1 
min at 4 °C, then rinsed 3x with PBS. Positive control samples were incubated with 0.2, 
1, and 5 U DNase I (Fermentas) for 1 h at 37 °C in the rxn buffer provided by the 
manufacturer. Samples were incubated with 10 mM TUNEL reaction mixture (in situ cell 
death detection kit, fluorescein, Roche) for 30 min at 37 °C in the dark, rinsed 3x with 
PBS. 
 
5’ End-labeling: The DNA primer designed for reverse transcription of helix 18 of the 
small yeast ribosomal subunit was purchased from Integrated DNA Technologies.  γ-32P 
5’ end-labeling was performed as previously described (4).  
 
Reverse Transcription: Total RNA extracted from cisplatin-treated yeast cells was used 
as a template for RT. Yeast cells were inoculated at 5 × 106 cells/mL into cisplatin-
containing SD-URA and grown for 6 h. Total RNA was isolated using a MasterPure 
Yeast RNA Extraction kit (Epicentre) and resuspended in 10 mM Tris-HCl (pH 7.5) and 
1 mM EDTA to a final concentration of 10 mg/mL. For primer extension, 1 mg of RNA 
template was annealed to 100 pmol of the specified 5’ end-labeled primer in the 
manufacturer’s reaction buffer and incubated in the presence of AMV Reverse 
Transcriptase (Fermantas) for 1.75 h at 42°C. The resulting cDNA products were diluted 
in loading buffer containing 0.005% (w/v) xylene cyanol and bromophenol blue and 
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analyzed by 8% dPAGE. Bands were visualized using a GE phosphor screen in 
conjunction with a Storm phosphor screen imaging system and then quantified with 
ImageQuant 5.1 and normalized in Excel.  
 
 
Figure A.1. Accumulation of Pt atoms per yeast cell in yeast treated with cisplatin for 1, 
3, 6, 9, and 12 h. Results averaged from four independent experiments, presented as the 
means ± SD. 
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Figure A.2. Helix 18 of the yeast ribosome (green) is located in close proximity to the 
peptidyl transferase center within the small ribosomal subunit (light gray). Image created 
with PyMol from PDB files 3O30 and 3O5H (5). 
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Figure A.3. Primer extension analysis of RNA isolated from 100 mM cisplatin-treated 
BY4741 at 0, 1, and 3 h shows a time-dependent accumulation of Pt2+ at the indicated 
purine residues (red arrowheads) beginning as early as 1 h following treatment. Specific 
platination sites are conserved after 6 h continuous exposure to drug (Figure 2.5). 
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Table A.1. Pt atoms accumulated in yeast RNA or DNA 
                                                         [Cisplatin] 
 100 mM 200 mM 
mRNA (Pt/nt, 6 h) (1.05 + 0.58) x 10-5 (3.53+0.40) x 10-5 
rRNA (Pt/nt, 6 h)a (5.77 + 0.96) x 10-5 (12.5 + 0.91) x 10-5 
Total RNA (Pt/nt, 6 h)a (6.97 + 0.69) x 10-5 (18.2 + 1.74) x 10-5 
Total RNA (Pt/nt, 12 h) (15.7 + 1.59) x 10-5 (56.6 + 6.46) x 10-5 
DNA (Pt/nt, 12 h) (60.2 + 8.22) x 10-5 (199 + 30.2) x 10-5 
Pt atoms on DNA from one 
yeast cell (104)b 
2 6 
Pt atoms on RNA from one 
yeast cell (104)b 
7–34 24–120 
a There is a small but statistically significant increase in Pt/nt values in total RNA vs. 
rRNA at 200 mM cisplatin treatment, but not at 100 mM cisplatin treatment. A major 
difference between these two cell populations is the number of viable, dividing cells 
(60% at 100 uM and only 30% at 200 uM cisplatin treatment, manuscript Table 1). It is 
possible that the cells in 200 uM cisplatin have begun processing the most heavily 
platinated rRNA, depleting it from the ‘full-length’ population. 
b At 12 h, calculation based on the mass of DNA and RNA in one haploid S. cerevisiae 
cell (6). 
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APPENDIX B 
 
SUPPORTING INFORMATION FOR CHAPTER III: PICAZOPLATIN, AN 
AZIDE-CONTAINING PLATINUM (II) DERIVATIVE FOR TARGET 
ANALYSIS BY CLICK CHEMISTRY 
 
Materials and Methods 
General Comments: Materials were purchased from commercial vendors and used 
without further purification unless noted otherwise. Anhydrous THF was purchased from 
EMD Millipore. 2-Methylpyridine-4-carboxylic acid, LiAlH4, diphenyl phosphorylazide, 
and 1,8-diazabicycloundec-7-ene (DBU) were purchased from TCI America. K2PtCl4 
was purchased from Strem Chemicals, Inc. and deuterated solvents were purchased from 
Cambridge Isotope Laboratories, Inc. Alexa Fluor 488 DIBO alkyne fluorescent dye was 
purchased from Life Technologies. Column chromatography was performed on Silica 
Gel Premium Rf (Sorbent Technologies, 75–200 µm).  
1H, 13C, and 195Pt NMR spectra were recorded in d6-acetone or CDCl3 using a 
Varian Mercury 300 MHz (1H: 300.09 MHz), Varian Inova 500 MHz (1H: 500.11 MHz, 
13C: 125.76 MHz), or Bruker Advance III HD 600 MHz (1H: 600.02 MHz, 195Pt: 128.99 
MHz) NMR spectrometer with Prodigy multinuclear broadband cryoprobe. Chemical 
shifts (δ) are expressed in ppm relative to the residual acetone (1H: 2.05 ppm) or CHCl3 
(1H: 7.27 ppm, 13C: 77.23) or the external reference K2PtCl4 (195Pt: –1604 ppm). IR 
spectra were obtained from neat solids on a Nicolet 6700 FT-IR instrument with diamond 
crystal ATR attachment. Gels were visualized with methylene blue stain or radiolabelled 
phosphate imaging (GE Storm 825), and UV exposure (AlphaImager HP System). High 
resolution mass spectra were recorded on a JEOL MS-Route mass spectrometer. MALDI 
spectra were acquired on an Applied Biosystems 4700 Proteomics Analyzer instrument at 
the Oregon State University mass spectrometry facility. The project described was 
supported, in part, by Award Number P30ES000210 from the National Institute of 
Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). The 
content herein is solely the responsibility of the authors and does not necessarily 
represent the official views of NIEHS or NIH. The authors acknowledge and sincerely 
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thank the Biomolecular Mass Spectrometry Core of the Environmental Health Sciences 
Core Center at Oregon State University. 
All DNA substrates were purchased directly from Integrated DNA Technologies, 
Inc., dissolved in nanopure ddH2O to a final stock concentration of 1 or 10 mM, and used 
directly without further purification. The yeast sarcin-ricin loop (SRL) RNA construct 
was purchased from Dharmacon, Inc., 2’-ACE deprotected according to the 
manufacturer’s protocol, and stored as a 1 mM solution in nanopure ddH2O. All DNA 
and RNA substrates were stored in aliquots at –30 °C. 
 
5-(Azidomethyl)-2-methylpyridine (ligand): 2-Methylpyridine-4-carboxylic acid (1.00 
g, 7.3 mmol) suspended in dry THF (20 mL) was cooled on ice and purged with N2. A 
solution of LiAlH4 (0.41 g, 10.8 mmol) in dry THF (20 mL) under N2 was slowly added 
to the carboxylic acid. Upon completion, the flask was removed from the ice and stirred 
another hour at rt. The reaction was quenched carefully with H2O (0.5 mL) and then 
~10% aq. KOH soln (0.5 mL). The slurry was dried (MgSO4), filtered, and evaporated in 
vacuo to afford the crude alcohol as a thick yellow oil (0.28 g, 2.27 mmol). To a solution 
of the crude oil (0.28 g, 2.27 mmol) in toluene (10 mL) was slowly added diphenyl 
phosphorylazide (0.60 mL, 2.81 mmol), then DBU (0.45 mL, 2.95 mmol), and the 
mixture stirred in the dark at rt for 18 h. The reaction mixture was then washed with 1M 
HCl soln (3 x 20 mL) and the combined aqueous layers were neutralized with an excess 
of solid NaHCO3. The aqueous layer was extracted with Et2O (5 x 30 mL), dried 
(Na2SO4), and evaporated in vacuo to obtain a light-yellow oil. The oil was purified by 
flash silica gel column chromatography (EtOAc) to afford the ligand (0.19 g, 1.3 mmol, 
18% from the acid) as a pale-yellow oil. Rf = 0.50 (EtOAc). 1H NMR (500 MHz, CDCl3): 
δ 8.45 (Ar H, d, 1H, J = 2.3 Hz), 7.56 (Ar H, dd, 1H, J = 2.3, 8.0 Hz), 7.19 (Ar H, d, 1H, 
J = 8.0 Hz), 4.33 (CH2N3, s, 2H), 2.57 (CH3, s, 3H); 13C NMR (126 MHz, CDCl3): δ 
158.8, 148.8, 136.4, 128.2, 123.5 (Ar C), 52.1 (CH2N3), 24.3 (CH3) ; IR ν (N3), very 
strong, 2097 cm.–1 
 
cis-Ammine(5-azidomethyl-2-methylpyridine)diiodoplatinum(II), iodinated 
picazoplatin: To a clear-red solution of K2PtCl4 (0.50 g, 1.20 mmol) in H2O (15 mL) 
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was added KI (1.0 g, 6.0 mmol) and the reaction was stirred in the dark until all of the KI 
had dissolved. 5-(Azidomethyl)-2-methylpyridine (0.13 g, 0.96 mmol) in H2O (10 mL) 
was added dropwise over ca. 1 h. The resulting brown precipitate was then filtered and 
washed with cold H2O and re-suspended in H2O (10 mL). To this suspension was slowly 
added 30% aq. NH3 soln  (0.25 mL, 4 mmol) and the reaction watched closely for the 
brown solid to turn yellow in color. After ca. 2 h stirring at rt, the yellow solid was 
filtered and washed with excess H2O and dried in vacuo. The crude complex was purified 
by flash silica gel column chromatography (1:1 acetone/benzene) to furnish the product 
(0.13 g, 0.22 mmol, 19%) as a yellow solid. Rf = 0.64 (1:1 acetone/benzene). 1H NMR 
(500 MHz, d6-acetone): δ 9.04 (Ar H, d, 1H, J = 2.1 Hz, 3JPt-H = 37 Hz), 7.85 (Ar H, dd, 
1H, J = 2.1, 8.1 Hz), 7.53 (Ar H, d, 1H, J = 8.1 Hz), 4.63 (CH2N3, s, 2H), 3.13 (CH3, s, 
3H). 13C NMR (126 MHz, d6-acetone): δ 161.7, 153.3, 138.8, 132.4, 127.7 (Ar C), 51.3 
(CH2N3), 26.8 (CH3) 195Pt NMR (107.5 MHz, d6-acetone): δ –3259 (Pt). HRMS (ESI) 
m/z calculated for C7H12N5I2Pt, 614.8830 (M++H); found, 614.8852. IR ν(N3), very 
strong, 2095 cm–1. 
 
Picazoplatin, cis-ammine(5-azidomethyl-2-methylpyridine)dichloroplatinum(II), 1: 
Cis-ammine(5-azidomethyl-2-methylpyridine)diiodoplatinum(II) (0.133 g, 0.22 mmol) 
was dissolved in a minimal amount of acetone. This yellow-orange solution was slowly 
dripped into a solution of AgNO3 (0.072 g, 0.43 mmol) in H2O (10 mL) and the solution 
stirred in the dark for 2 h. The resulting yellow-opaque solution was placed under high 
vacuum with gentle heating for 15 min, then filtered through a 0.2 µm syringe filter. 1 M 
HCl soln (ca. 4 drops) and KCl (1.0 g) were added to the clear-yellow filtrate, and the 
solution left to sit in the refrigerator overnight. The next day the yellow precipitate was 
filtered, rinsed with water, and dried in a dessicator to afford a light-yellow solid (0.052 
g,  0.12 mmol, 11 % from K2PtCl4). 1H NMR (300 MHz, d6-acetone): δ 9.34 (Ar H, d, 
1H, , J = 2.0 Hz,  3JPt-H = 37 Hz), 7.85 (Ar H, dd, 1H, J = 2.0, 8.1 Hz), 7.54 (Ar H, d, 1H, 
J = 8.1 Hz); 4.64 (CH2N3, s, 2H); 3.23 (CH3, s, 3H); 195Pt NMR (129  MHz, d6-acetone): 
δ –2041 (Pt); HRMS (ESI) m/z calculated for NaC7H11N5Cl2Pt, 453.9939 (M++Na); 
found, 453.9962; IR ν (N3), very strong, 2098 cm–1. 
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5-(Dimethylamino)-N-(2-propynyl)-1-napthalenesulfonamide (dansyl alkyne 
fluorophore): The dansyl alkyne was synthesized according to previously published 
methods (Bolletta, F.; Fabbri, D.; Lombardo, M.; Prodi, L.; Trombini, C.; Zaccheroni, N. 
Organometallics 1996, 15, 2415-2417). 
 
Platinum activation (aquation): Cis-ammine(5-azidomethyl-2-methyl 
pyridine)diiodoplatinum(II), iodinated picazoplatin, (3.0 mg, 4.89 µmol) was added to a 
solution of AgNO3 in ddH2O (10 mM, 1 mL). The solution was incubated at 50 °C for 4 
to 18 h with stirring, at which time AgI precipitated as a white solid and was separated by 
centrifugation (10,000 RPM for 10 min). The resulting light orange supernatant was 
removed and used for DNA and RNA binding studies. Solutions were stored in the dark 
at 4 °C and used for up to 1 week. 
 
Platinum—DNA Duplex Binding (Figure 3.2a): The DNA duplex (280 µM each of 5’-
T5GGT6-3’ and 5’-A6CCA5-3’, typically 28 nmol) was folded by rapid heating to 90 °C 
and slow cooling to 4 °C in 10 mM Na2PO4 (pH 7.0), 100 mM NaNO3, and 1 mM 
Mg(NO3)2 . An activated solution of cis-ammine(5-azidomethyl-2-
methylpyridine)diiodoplatinum(II) was added in 2-fold excess and the solution was 
incubated at 37 °C for 4 h. Platinum bound DNA was purified with Sephadex G-25 
Medium size exclusion resin (GE Healthcare) on laboratory prepared spin columns 
(BioRad) to remove unbound platinum. The eluent was dried to completion by SpeedVac 
and the remaining pellet was either resuspended in ddH2O for click reactions or 
redissolved in a 50% v/v solution of ddH2O and formamide without loading dye for 
cleaner PAGE analysis and UV imaging.   
  
Platinum—DNA Duplex Click reaction (Figure 3.2a): Sodium ascorbate (18 µL, 10 
mM), CuI (18 µL, 10 mM), dansyl alkyne (10 µL, 2mM), and Et3N (10 µL, 7.2 M) were 
added to an aqueous solution of Pt-bound DNA (18 µL, 180 µM). The samples were 
incubated at 50 °C for 30 min to 4 h. The samples were then purified with Sephadex G-
25 Medium spin-columns. The samples were dried in vacuo and then re-suspended in an 
equal volume mixture of ddH2O and formamide. The solutions were then analyzed using 
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20% (29:1) mono/bis polyacrylamide gels. 
  
Platinum—DNA Single Strand Binding (Figure 3.2c): Single-stranded GG DNA (80 
µM of 5’- T5GGT6-3’, typically 8 nmol) for MALDI- MS analysis was reacted with 
activated cis-ammine(5-azidomethyl-2-methylpyridine)diiodoplatinum(II) in 4-fold 
excess at 37 °C for 18 h. Platinum-bound DNA was purified with Sephadex G-25 
Medium size exclusion resin (GE Healthcare) on laboratory prepared spin columns 
(BioRad) to remove unbound platinum. The eluent was dried to completion by SpeedVac 
and the remaining pellet was stored at –30 °C until use. 
  
Platinum—DNA Single Strand Click reaction (Figure 3.2c): The platinum-bound 
DNA pellet was resuspended in a solution of Na2PO4 (pH 7.0) (88.5 µL, 100 mM), 
CuSO4  (5 µL, 1 mM), dansyl alkyne (2.5 µL, 2 mM), and sodium ascorbate (4 µL, 5 
mM). This solution was reacted at 50 °C for 1 h and subsequently purified with Sephadex 
G-25 Medium spin-columns. The samples were dried to completion by SpeedVac and the 
remaining pellet was stored at –30 °C until use. 
 
MALDI Mass Spectrometry (Figure 3.2c): MALDI-MS samples were prepared 
according to the previously described protocol (Chapman, E. G.; DeRose, V. J. J. Am 
Chem. Soc. 2010, 132, 1946-1952). Briefly, dried DNA samples were re-suspended in 
deionized water and puriﬁed using C18 ZipTips. ZipTips were washed by aspiration three 
times with 1:1 MeCN/H2O and equilibrated by washing three times with 0.1% 
triﬂuoroacetic acid (TFA). DNAs were bound to the tip by repeated aspiration of the 
analyte solution. Bound DNA was washed three times by aspiration with 0.1% TFA, 
three times with deionized water, and then eluted from the column using two washes of 
1:1 MeCN/H2O. The eluent was dried to completion by SpeedVac and re-suspended in a 
matrix consisting of 375 mM 2’,4’,6’-trihydroxyacetophenone (THAP, Sigma-Aldrich), 
30 mM diammonium citrate in 3:1 EtOH/H2O, with added NH4+ loaded Dowex cation 
exchange beads (Aldrich) and applied to the sample plate. 
 
Platinum—DNA Hairpin Binding (Figure 3.3b): The DNA hairpin (400 µM of 5’-
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TATGGTATTTTTATACCATA-3’, typically 40 nmol) and added trace 32P-labeled DNA 
hairpin was folded by rapid heating to 90 °C and slow cooling to 4 °C in 10 mM Na2PO4 
(pH 7.0), 100 mM NaNO3, and 1 mM Mg(NO3)2 . An activated solution of cis-ammine(5-
azidomethyl-2-methylpyridine)diiodoplatinum(II) was added in 2-fold excess and the 
solution was incubated at 37 °C for 18 h. Pt-bound DNA was purified with Sephadex G-
25 Medium size exclusion resin (GE Healthcare) on laboratory prepared spin columns 
(BioRad) to remove unbound platinum. The eluent was dried to completion by SpeedVac 
and the remaining pellet was stored at –30 °C until use. 
 
Platinum—DNA Hairpin Click reaction (Figure 3.3b): The platinum-bound DNA 
pellet was resuspended in one of two click-capable solutions: (A) Na2PO4 (pH 7.0) (88.5 
µL, 100mM), CuSO4  (5 µL, 1 mM), dansyl alkyne (2.5 µL, 2 mM), and sodium ascorbate 
(4 µL, 5 mM) or (B) Na2PO4 (pH 7.0) (88.5 µL, 100mM), CuI (5 µL, 1 mM), Et3N (2 µL, 
2 mM), dansyl alkyne (2.5 µL, 2 mM), and sodium ascorbate (4 µL, 5 mM). These 
solutions were prepared either in the presence or absence of 0.6% v/v CH3CN. 
 
Platinum—RNA Binding (Figure 3.4b): A solution of 100 µM SRL RNA (5’-UGA 
ACU UAG UAC GAG AGG AAC AGU UCA CCC CCC GCC GCG AAG CUA CCA 
UCC GCU-3’, typically 10 nmol) was folded by rapid heating to 90 °C and slow cooling 
to 4 °C in 10 mM Na2PO4 (pH 7.0), 100 mM NaNO3, and 1 mM Mg(NO3)2 . Activated 1 
was added in 4-fold excess and the mixture was incubated 37 °C for 18 h. Pt-bound RNA 
was purified with Sephadex G-25 Medium size exclusion resin (GE Healthcare) on 
laboratory prepared spin columns (BioRad) to remove unbound Pt. The eluent was dried 
to completion by SpeedVac and the remaining pellet was stored at –30 °C until use. 
 
Platinum—RNA Click reaction (Figure 3.4b): The Pt-bound RNA pellet was 
resuspended in a buffered premixed solution containing 0.4 or 0.8 equivalents CuI (4 or 8 
µL, 1 mM), Et3N (2 µL, 2 mM), CH3CN (6 µL , 10% v/v), excess dansyl alkyne (2.5 µL, 
2 M), and pH 7.0-buffered sodium phosphate (85.5 µL or 81.5 µL, 100 mM, pH 7.0).  
This mixture was incubated at 50 °C for 1 h and purified by Sephadex G-25 Medium 
spin-columns. Samples were analyzed by dPAGE as described for DNA, on a 10 cm gel. 
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Cell Cultures and Treatments (Figure 3.5): S. cerevisiae strain BY4741 (MATa; 
his3Δ1; leu2Δ0; met15Δ0; ura3Δ0) was a gift from the Stevens laboratory at the 
University of Oregon. Plated cells were grown on YEPD agar plates (1% yeast extract, 
2% peptone, 2% glucose, and 2% agar). Liquid cultures were grown on Synthetic 
Complete medium (SC) consisting of 0.67% yeast nitrogen base and 2% glucose 
supplemented with amino acids and nucleotide bases and maintained in the dark at 30°C 
with shaking at 200 rpm. Culture growth was measured by absorbance at 600 nm (1 
AU600 = 2.0 × 107 cells/mL). A 5 mM picazoplatin stock was used for all picazoplatin 
treatments. Yeast cultures were pregrown to an OD600 of 5 (10.0 x 107 cells/mL) and then 
diluted to an OD600 of 0.25 (5.0 x 106 cells/mL) in picazoplatin-containing media (final 
concentration of 0, 250, or 500 µM drug).  10 mL cultures were grown for 12 h at 30°C 
with shaking at 200 rpm. Total RNA was extracted from picazoplatin-treated yeast using 
the MasterPure Yeast RNA Purification Kit (Epicentre) according to a modified 
manufacturer’s protocol. Total RNA concentration was calculated using absorbance at 
260 nm (1AU = 40 µg/mL) and all samples were dried to completion by SpeedVac and 
resuspended in ddH2O to a final normalized concentration of 1 ug/µL. 
 
Total RNA Click Reaction: 1 µL of total RNA was added to a 10 µL aqueous solution 
containing 0.5 µL (20 U) RiboGuard RNAse Inhibitor (0.5 µL, 20 U, Epicentre) and 
excess Alexa Fluor 488 DIBO Alkyne (1 µL, 0.5 mM). The reaction proceeded overnight 
at 37°C. Unreacted fluorophore was removed using an RNeasy mini kit (Qiagen) 
according to a modified manufacturer’s protocol. The 20 µL eluent from the spin column 
was diluted with 20 µL of formamide and the samples were analyzed on a 10% (29:1) 
mono/bis polyacrylamide gel (as described previously for in vitro click reactions). 
 
Yeast 5.8S Ribosomal RNA Sequence:  5’-AAACUUUCAA CAACGGAUCU 
CUUGGUUCUC GCAUCGAUGA AGAACGCAGC  GAAAUGCGAU 
ACGUAAUGUG AAΨUGCAGAA UUCCGUGAAU CAUCGAAUCU 
UUGAACGCAC AUUGCGCCCC UUGGUAUUCC AGGGGGCAUG 
CCUGUUUGAG CGUCAUUU-3’. Sequence from Rubin et. al.1  
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Figure B.2. Complete MALDI spectrum of T6GGT5 after binding with picazoplatin (1). 
Figure B.1. Complete MALDI spectrum of T6GGT5 single-strand DNA oligomer. 
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Figure B.3. Complete MALDI spectrum of platinated T6GGT5 after click to dansyl alkyne. 
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Figure B.4. 1H NMR (300 MHz, d6-acetone, 298 K) of picazoplatin, 1. 
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Figure B.7 (Materials and Methods):  
Platinum—RNA Binding: A solution of 60 µM SRL RNA (5’-UGA ACU UAG UAC 
GAG AGG AAC AGU UCA CCC CCC GCC GCG AAG CUA CCA UCC GCU-3’, 
typically 6 nmol) with added trace 32P-labeled SRL RNA was folded by rapid heating to 
90 °C and slow cooling to 4 °C in 10 mM phosphate buffer (pH 7.0), 100 mM NaNO3, 
and 1 mM Mg(NO3)2 . Activated 1 was added in 4-fold excess and the mixture was 
incubated 37 °C for 18 h. Pt-bound RNA was purified with Sephadex G-25 Medium size 
exclusion resin (GE Healthcare) on laboratory prepared spin columns (BioRad) to 
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Figure B.5. 195Pt NMR (129 MHz, d6-acetone, 298 K) of picazoplatin, 1, baseline corrected. 
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Figure B.6. High-resolution mass spec. of picazoplatin, 1, with the molecular ion peak 
(M+Na+) at 453.9962 m/z. 
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remove unbound Pt. The eluent was dried to completion by SpeedVac and the remaining 
pellet was stored at –30 °C until use.
 
Platinum—RNA Click reaction: The Pt-bound RNA pellet was resuspended in one of 
two click-capable solutions: (A) Phosphate buffer (pH 7.0) (88.5 µL, 100 mM), CuSO4  (5 
µL, 1 mM), dansyl alkyne (2.5 µL, 2 mM), and sodium ascorbate (4 µL, 5 mM) or (B) 
Phosphate buffer (pH 7.0) (88.5 µL, 100mM), CuI (5 µL, 1 mM), Et3N (2 µL, 2 mM), 
dansyl alkyne (2.5 µL, 2 mM), and sodium ascorbate (4 µL, 5 mM). Solutions were 
prepared in the presence or absence of 0.6% v/v CH3CN. Reactions were incubated at 50 
°C for 1 h ,purified by Sephadex G-25 Medium spin-columns, and analyzed as described 
for DNA, on an 8 cm PAGE gel. 
 
 
 
Figure B.7. (a) RNA SRL hairpin with 1 bound and tagged (clicked) with the alkyne 
fluorophore. Potential Pt binding sites are indicated by starred nucleotides. (b) Fluorescent 
labeling of RNA SRL mimic hairpin by click chemistry. Lane 1 contains nonplatinated RNA 
SRL and shows no nonspecific RNA-fluorophore interaction. Lanes 2-5 contain platinated 
RNA under varying click condition sets; lanes 3 and 5 show efficient RNA-fluorophore 
labeling in the presence of 0.6% acetonitrile.  
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APPENDIX C 
 
SUPPORTING INFORMATION FOR CHAPTER IV: CLICK FLUORESCENT 
LABELING AND ENZYMATIC MAPPING OF PLATINUM (II) COVALENT 
DRUG MODIFICATIONS IN SACCHAROMYCES CEREVISIAE  
RIBOSOMAL RNA 
 
Materials and Methods 
Platinum Drug Treatment and RNA Extraction from S. cerevisiae: S. cerevisiae 
strain BY4741 (MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0) was a generous gift from the 
Stevens Laboratory at the University of Oregon. Cisplatin and oxaliplatin were purchased 
from Sigma Aldrich. Picazoplatin was synthesized as described previously (1). Plated 
cells were grown on YEPD agar plates (1% yeast extract, 2% peptone, 2% glucose, and 
2% agar). Liquid cultures were grown on Synthetic Complete medium (SC) consisting of 
0.67% yeast nitrogen base and 2% glucose supplemented with amino acids and 
nucleotide bases and maintained in the dark at 30°C with shaking at 200 rpm. Culture 
growth was measured by absorbance at 600 nm (1 AU600 = 2.0 × 107 cells/mL). A 5 mM 
cisplatin, oxaliplatin, or picazoplatin stock was used for all platinum treatments. Yeast 
cultures were pregrown to an OD600 of 5 (10.0 x 107 cells/mL) and then diluted to an 
OD600 of 0.25 (5.0 x 106 cells/mL) in platinum-containing media (final concentration 
varying between 0 and 500 µM drug). 10—50 mL cultures were grown for 12 h at 30°C 
with shaking at 200 rpm. Total RNA was extracted from cisplatin-, oxaliplatin-, or 
picazoplatin-treated yeast using the MasterPure Yeast RNA Purification Kit (Epicentre) 
according to a modified manufacturer’s protocol. Total RNA concentration was 
calculated using absorbance at 260 nm (1AU = 40 µg/mL) and all samples were dried to 
completion by SpeedVac and resuspended in ddH2O to a final normalized concentration 
of 10 ug/µL.  
 
Fluorescent Post-Labeling of RNA from Picazoplatin-treated S. cerevisiae: 0.5 µL of 
total RNA was added to a 10 µL aqueous solution containing 0.5 µL (20 U) RiboGuard 
RNAse Inhibitor (0.5 µL, 20 U, Epicentre) and excess Alexa Fluor 488 DIBO Alkyne (1 
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µL, 0.5 mM). The reaction proceeded overnight at 37°C. Unreacted fluorophore was 
removed using an RNeasy mini kit (Qiagen) according to a modified manufacturer’s 
protocol. The 20 µL eluent from the spin column was diluted with 20 µL of formamide 
and the samples were analyzed on a 10% (29:1) mono/bis polyacrylamide gel. RNA 
purity and content were assessed with a methylene blue stain. Fluorescence images were 
collected with an AlphaImager and processed (false colored) using Adobe Photoshop.  
 
Platination of SRL RNA in vitro: Synthetic RNA was purchased from Dharmacon, 
consisting of the model SRL plus a short extended sequence designed for RT primer 
annealing (italicized). For all in vitro studies, cisplatin was aquated as described 
previously (1). A solution of 100 µM SRL RNA (5’-UGA ACU UAG UAC GAG AGG 
AAC AGU UCA CCC CCC GCC GCG AAG CUA CCA UCC GCU-3’, typically 10 
nmol) was folded by rapid heating to 90 °C and slow cooling to 4 °C in 10 mM Na2PO4 
(pH 7.0), 100 mM NaNO3, and 1 mM Mg(NO3)2 . Activated cisplatin was added in 0—2 
fold excess and the mixture was incubated 37 °C for 18 h. Non-activated oxaliplatin was 
added in 0—10 fold excess. Pt-bound RNA was purified with Sephadex G-25 Medium 
size exclusion resin (GE Healthcare) on laboratory prepared spin columns (BioRad) to 
remove unbound Pt. The eluent was dried to completion by SpeedVac and the remaining 
pellet was stored at –30 °C until use.  
 
Primer Extension Analysis of Pt-bound RNA in vitro: DNA primers designed for 
reverse transcription of the model SRL and S. cerevisiae rRNA were purchased from 
Integrated DNA Technologies (5’-AGC GGA TGG TAG CTT CGC GGC-3’ for the SRL 
region in vitro and in vivo and 5’-CTA TTG CGG TAA CAT TCA TC-3’ for the PTC). 
γ-32P 5′ end-labeling was performed as described previously (2). For primer extension of 
a synthetically platinated RNA, 100 pmol of the prepared RNA template was annealed to 
10 pmol of the SRL DNA primer with trace γ-32P primer and incubated with AMV 
Reverse Transcriptase (Fermentas) according to a modified manufacturer’s protocol for 
1.75 h at 42 °C. For the sequencing lanes, a synthetic template DNA (The resulting 
cDNA products were diluted in loading buffer containing 0.005% (w/v) xylene cyanol 
and bromophenol blue and analyzed by 12% dPAGE. Bands were visualized using a GE 
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phosphor screen in conjunction with a Storm phosphor screen imaging system and then 
quantified with ImageQuant 5.1 and normalized in Excel. 
 Sequencing reference lanes were generated with a Sequenase Version 2.0 DNA 
Sequencing kit (USB Corporation) following the manufacturer’s protocol, using an 
appropriate DNA template (Integrated DNA Technologies) and the γ-32P 5′ end-labeled 
primers used for the primer extension reactions. 
 
Primer Extension Analysis of Pt-bound RNA in vivo: For primer extension, 1 µg of 
RNA template was annealed to 100 pmol of the specified 5′ end-labeled primer in the 
manufacturer’s reaction buffer and incubated in the presence of AMV Reverse 
Transcriptase (Fermantas) for 1.75 h at 42 °C. The resulting cDNA products were diluted 
in loading buffer containing 0.005% (w/v) xylene cyanol and bromophenol blue and 
analyzed by 8% dPAGE. Bands were visualized using a GE phosphor screen in 
conjunction with a Storm phosphor screen imaging system and then quantified with 
ImageQuant 5.1 and normalized in Excel. Sequence reference lanes were generated as 
described above.  
 
Figure Preparations: All figures containing crystal structure data were prepared in 
PyMOL (www.pymol.org) using PDB files obtained from the RCSB Protein Data Bank. 
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Table C.1. Estimation of Pt accumulation in different RNAs based on fluorescent 
labeling following treatment with 250 µM picazoplatin (5 ug reaction). The in-gel 
detection limit of clicked Alexa Fluor 488 alkyne (in 10% 29:1 mono/bis polyacrylamide) 
is approximately 1 pmol, and we estimate that we can visualize concentrations as low as 
1 Pt per 10,000 nt in these RNA species (data not shown). Molnt RNA determined using 
an average nucleotide molecular weight of 340 gnt. 
RNA (ug) molnt RNA Total nt mol RNAs mol AF488* Pt/RNA 
rRNA 4.5 ug 1.4e-8 ~6000/ribosome 2.2e-12 0.94e-12 ~0.4 
tRNA 0.5 ug 1.5e-9 ~100/tRNA 1.5e-11 0.80e-12 ~0.8 
*Mol of Alexa Fluor 488 alkyne in each band, based on calibration gel. Each Alexa Fluor 
488 alkyne corresponds to one Pt atom, assuming 100% click efficiency. 
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Figure C.1. Full sequence analyzed by primer extension analysis of the S. cerevisiae
sarcin ricin loop and adjacent helices from ribosomal RNA treated with 0—200 µM 
cisplatin. Dideoxy sequencing ladder labeled by A, U, C, and G. Cisplatin-induced stop 
sites are denoted by arrowheads and summarized in the secondary structure with orange 
lettering. Nucleotides which were not analyzed in this particular experiment are in gray. 
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Figure C.2. Primer extension analysis of the sarcin-ricin loop (SRL) region in 
ribosomal RNA extracted from S. cerevisiae treated with 0—300 µM cisplatin. This 
experiment used a primer designed to probe further upstream than the one in Figure 3. 
Dideoxy sequencing ladder labeled by A, U, C, and G. Cisplatin-induced stop sites are 
denoted by asterisks (*) and represent nucleotides 3’ to a stable platinum adduct. 
Colored asterisk denotes primary stop site in terminal SRL region according to line plot 
analysis. Predicted platinum crosslinks between adjacent purines based on experimental 
results are colored in bold on the S. cerevisiae secondary structure map. 
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Figure C.3. Primer extension analysis of the S. cerevisiae peptidyl transferase center 
from ribosomal RNA treated with 0—300 μM cisplatin. Cisplatin-induced stop sites are 
denoted by arrowheads and summarized in the secondary strucutre with orange lettering. 
Endogenous ribosomal RNA modifications (i.e. 2’-OCH3) and regions of stable 
secondary structure which also inhibit primer extension in the absence of platinum are 
denoted by red lines. Nucleotides which were not analyzed in this particular experiment 
are in gray. Nucleotides protected from Pt indicated in green. 
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